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Summary 
The Norwegian Scientific Committee for Food Safety (VKM) received a request from the 
Norwegian Food Safety Authority to assess whether the Tolerable Upper Intake Level (UL) of 
folic acid should be amended in light of new scientific evidence suggesting a possible link 
between high intake levels of folic acid and risk of cancer. Folic acid obtained from both food 
supplements and fortified foods should be assessed. Folic acid is a synthetic form of folate 
and is commonly used in food supplements and in food fortification because of its stability 
and bioavailability. Folic acid is reduced, methylated and released into the circulation. Natural 
folates occur in reduced forms, e.g. as tetrahydrofolate (THF), which are unstable and may 
thus loose biochemical activity during harvesting, storage, processing, and preparation.  
Folate is cofactor for enzymes in one-carbon metabolism where it provides one-carbon units 
for the formation of RNA and DNA. Folate is also essential for the normal functioning of the 
methionine cycle, which is responsible for both the conversion of homocysteine to 
methionine and the production of the universal methyl donor S-adenosylmethionine (SAM). 
SAM donates its methyl group to more than 100 methyltransferases for a wide range of 
substrates such as DNA, hormones, proteins, neurotransmitters and membrane 
phospholipids.  
While no Tolerable Upper Intake Level (UL) has been derived for natural dietary folates, the 
Scientific Committee on Food (SCF, 2000) set an UL of 1000 µg folic acid per day in 2000. 
The UL was set because it was found that high intakes of folic acid could correct 
megaloblastic anemia, which is the hallmark manifestation of vitamin B12 deficiency. In this 
way folic acid may mask vitamin B12 deficiency which again may cause irreversible 
neurological damage. The ULs for children and adolescents (1-17 years) were adjusted on 
the basis of body weight and range from 200 to 800 μg/day. The UL for folic acid has been 
reassessed by other authorities, most recently in 2009 by EFSA (EFSA, 2009), who upheld an 
UL of 1 mg/day. 
In 2009, Ebbing et al. published results from combined analyses of two randomised, 
placebo-controlled trials with B-vitamin supplementation in patients with ischemic heart 
disease. They found an increased risk of cancer in those who were randomised to receive 
folic acid in combination with vitamin B12 (Ebbing et al., 2009). Folates are important for cell 
division. It is therefore possible that tumor growth or growth of premalignant cells may be 
stimulated by high concentrations of folate in the blood. Another concern with use of folic 
acid is circulating unmetabolised folic acid (UMFA) which is often found at intakes of more 
than 200 µg per day (Kelly et al., 1997). It has been argued that UMFA could affect 
homeostatic regulation of folate (Smith et al., 2008), and that it may reduce natural-killer cell 
cytotoxicity (Troen et al., 2006). In vitro studies have also demonstrated that folic acid can 
down-regulate tumor suppressor genes (Lubecka-Pietruszewska et al., 2013). 
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This opinion addresses the question whether the current UL for folic acid should be amended 
based on new scientific evidence. Furthermore, VKM has been requested to estimate folic 
acid intake from food supplements and from foods that are fortified with folic acid, in all age 
groups in the population above 1 year. In addition, possible consequences of amending the 
maximum limit for folic acid in food supplements should be discussed. 
In the literature search for this opinion (articles published from 2009 to 15 October 2014 
were obtained), we found eight meta-analyses and five single studies where the aims were 
to study the relation between folic acid supplementation and incidence of cancer. Meta-
analyses including studies in which folic acid was used in combination with other 
supplements were not included in the final evaluation, as the effect of folic acid could not be 
distinguished from the effect of the other substances. Only one meta-analysis was therefore 
considered relevant for the evaluation of UL for folic acid; a meta-analysis of patients with 
colorectal adenomas who received 1 mg folic acid per day for 3-6 years (Figueiredo et al., 
2011). No increased risk of colorectal adenomas or cancer was found in this meta-analysis. 
Nor did the included single studies report increased risk of colorectal cancer following folic 
acid supplementation (Gao et al., 2013; Wu et al., 2009). 
Brain tumor and childhood leukemia were investigated in two case-control studies in 
offspring of women using folic acid supplementation during pregnancy (Amigou et al., 2012; 
Milne et al., 2012). Both studies indicated no negative effects of folic acid supplementation 
during pregnancy.  
A secondary analysis of one of the single studies on colorectal adenomas found a statistically 
significant increased risk of prostate cancer following folic acid supplementation (Figueiredo 
et al., 2009). However, the small number of prostate cancer cases in this single study does 
not make this result robust.  
In six studies circulating UMFA was reported among subjects who used folic acid 
supplements or who were subjected to folic acid food fortification. Whether UMFA 
contributes to the development of cancer or other undesirable health effects is not known. 
These studies do not provide new evidence for amending the existing UL for folic acid. 
About 26% of women and 18% of men aged 18-70 years participating in the nationwide 
dietary survey Norkost 3, reported to take folic acid supplements. The mean intake of folic 
acid among users was 149 µg/day among women and 172 µg/day among men. Among 
pregnant women participating in The Norwegian Mother and Child Cohort Study, 62% 
reported use of folic acid supplements in 2008. Mean folic acid intake was 388 µg/day, and 
the 95th percentile was 800 µg/day. Information on intake of folic acid from supplements for 
other age groups is not available. 
Intake of folic acid from fortified foods is not available in the national food consumption 
surveys for any age groups. However, according to a Norwegian model for food fortification 
from 2006 and later updates (last update in 2013), 53 µg folic acid per 100 kcal can be 
added to food and drinks without exceeding the UL for folic acid in any age groups. With the 
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current levels of folic acid in food supplements and current levels in fortified products, the UL 
for folic acid will not be exceeded. 
VKM was also requested to assess the impact of any increase of the current maximum limit 
of 200 µg for folic acid in supplements. Increasing the maximum limits in food supplements 
to 400 µg will imply exceedance of UL for children younger than 6 years and an intake close 
to UL in children 7-10 years. An increase in the maximum limits in food supplements to 
600 µg will imply exceedance of UL for children younger than 10 years and an intake close to 
UL in children 11-14 years. Increasing the maximum limits in food supplements to 400 µg 
or 600 µg will not imply exceedance of UL among adults as evaluated in the Norwegian food 
fortification model (VKM, 2013). 
No new evidence for increased risk of cancer related to folic acid was found in the reviewed 
literature. Studies in subjects who had a history of colorectal adenomas, a group considered 
particularly vulnerable to develop cancer, reported no increased risk of colon cancer or 
adenomas after 3 -5 years of treatment with 1000 µg of folic acid per day. VKM therefore 
concludes that studies published after 2009 and until 15 October 2014 examining cancer do 
not provide support to alter the existing UL for folic acid. 
Key words: Folic acid, tolerable upper intake level, UL, risk assessment, VKM, 
Norwegian Scientific Committee for Food Safety. 
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Sammendrag på norsk 
Vitenskapskomiteen for mattrygghet (VKM) har på oppdrag fra Mattilsynet blitt bedt om å 
vurdere øvre trygt inntaksnivå (Tolerable Upper Intake Level; UL) for folsyre i lys av ny 
forskning som har antydet at det kan være en sammenheng mellom høyt inntak av folsyre 
og kreft. Folsyre er en syntetisk form for folat, og blir brukt i kosttilskudd og i berikning av 
mat og drikke fordi det er mer stabilt og absorberes bedre enn naturlige folater. I kroppen 
blir folsyre redusert, metylert og frigjort til sirkulasjonen. Naturlige folater forekommer i 
redusert form som tetrahydrofolat (THF), de er ustabile og blir lett nedbrutt ved innhøsting, 
lagring og tilberedning av matvarer. 
Folater overfører en-karbon-enheter i sentrale biokjemiske reaksjoner som 
aminosyrestoffskiftet og syntesen av puriner og pyrimidiner. Folat er viktig for normal 
funksjon i metioninsyklusen der homocystein omdannes til metionin, og i produksjon av den 
universelle metyldonoren S-adenosylmethionine (SAM). SAM donerer sin metylgruppe til mer 
enn 100 metyltransferaser for en lang rekke substrater, herunder DNA, hormoner, proteiner, 
nevrotransmittere og membranfosfolipider. 
Det er ikke fastsatt UL for naturlige folater, men for folsyre fastsatte EUs vitenskapskomite 
for næringsmidler (Scientific Committee on Food) i 2000 en UL på 1000 µg per dag (SCF, 
2000). Denne UL er basert på at et høyt inntak av folsyre kan korrigere megaloblastisk 
anemi som er et symptom på vitamin B12-mangel. På denne måten kan høye nivåer av 
folsyre maskere vitamin B12-mangel. Dette kan blant annet medføre at mangelen vedvarer, 
noe som igjen kan forårsake irreversible nevrologiske skader. UL for barn og ungdom (1-17 
år) ble justert på grunnlag av kroppsvekt til 200-800 µg/dag. UL for folsyre er revurdert av 
ulike andre myndigheter, senest i 2009 av EFSA, som opprettholdt UL på 1000 µg/dag 
(EFSA, 2009). 
I kombinerte analyser av to randomiserte studier på pasienter med iskemisk hjertesykdom 
ble det rapportert om økt forekomst av kreft hos de som ble randomisert til behandling med 
folsyretilskudd i kombinasjon med vitamin B12 (Ebbing et al., 2009). Folater er viktig for 
celledeling, og dermed vil tumorvekst og vekst av premaligne celler kunne bli stimulert ved 
høye folatkonsentrasjoner. Ikke-metabolisert folsyre (unmetabolised folic acid; UMFA) er 
påvist i blod ved inntak av folsyre fra beriket mat og/eller ved bruk av folsyretilskudd på over 
200 µg per dag (Kelly et al., 1997). UMFA kan påvirke den homeostatiske reguleringen av 
folat (Smith et al., 2008) og kan hemme cytotoksiske lymfocytter (Troen et al., 2006). In 
vitro-studier har også vist at folsyre kan nedregulere tumor suppressorgener (Lubecka-
Pietruszewska et al., 2013). 
Denne risikovurderingen er basert på en gjennomgang av vitenskapelig litteratur publisert 
etter 2009 for å se om det er behov for å endre den eksisterende UL for folsyre. Videre er 
VKM bedt om å beregne inntak av folsyre fra kosttilskudd og berikede produkter i alle 
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aldersgrupper i befolkningen over 1 år, og om å vurdere eventuelle helseskadelige 
konsekvenser av å endre den eksisterende maksimumsgrensen for folsyre i kosttilskudd. 
I litteratursøket (fra 2009 til 15 oktober 2014), ble det funnet åtte metaanalyser og fem 
enkeltstudier, som alle undersøkte sammenhenger mellom folsyretilskudd og forekomst av 
kreft. Sju av de åtte metaanalysene inkluderte studier som ga tilskudd med flere vitaminer i 
kombinasjon. Disse metaanalysene er ikke tillagt vekt i den endelige evalueringen av UL 
ettersom en eventuell effekt fra folsyre ikke kan skilles fra de andre vitaminene. Den ene 
metaanalysen med bare rene folsyreintervensjoner fant ingen økt risiko for 
tykktarmsadenomer (godartet epitelcellesvulst) eller tykktarmskreft etter 3-6 år med 1 mg 
folsyretilskudd blant pasienter allerede diagnostisert med tykktarmsadenomer (Figueiredo et 
al., 2011). Tilsvarende resultater ble rapporter i to randomiserte studier der 
intervensjonsgruppene ble gitt opp til 1 mg folsyre per dag uten økt risiko for tykktarmskreft 
(Gao et al., 2013; Wu et al., 2009).  
Forekomst av hjernesvulst og leukemi hos barn av mødre som hadde tatt folsyretilskudd i 
svangerskapet ble undersøkt i to kasus-kontrollstudier (Amigou et al., 2012; Milne et al., 
2012). Det ble ikke rapportert om negative helseeffekter i disse studiene.  
I en sekundæranalyse av et randomisert klinisk forsøk på pasienter med tykktarmsadenomer 
ble det funnet en statistisk signifikant økt risiko for prostatakreft ved bruk av folsyretilskudd 
(Figueiredo et al., 2009). Imidlertid er ikke resultatet fra denne ene studien robust på grunn 
av få prostatakrefttilfeller totalt sett. 
I seks studier ble det rapportert om sirkulerende UMFA hos individer som brukte 
folsyretilskudd eller mat beriket med folsyre. I hvilken grad UMFA bidrar til utvikling av kreft 
eller andre uønskede helseeffekter, er fortsatt uavklart. Disse studiene gir heller ikke 
grunnlag for å endre eksisterende UL for folsyre. 
Ca. 26 % av kvinnene og 18 % av mennene i en landsomfattende kostholdsundersøkelse 
blant norske menn og kvinner 18-70 år (Norkost 3) rapporterte å ta kosttilskudd med folsyre. 
Gjennomsnittlig inntak av folsyre fra tilskudd blant de som rapporterte slik bruk var 149 µg 
per dag hos kvinner og 172 µg per dag hos menn. I Den norske mor og barn-undersøkelsen 
rapporterte 62 % av gravide kvinner i 2008 at de brukte folsyretilskudd. Gjennomsnittlig 
folsyreinntak var 388 µg, og 95 % tok under 800 µg/dag. Informasjon om inntak av folsyre 
fra kosttilskudd er ikke tilgjengelig for andre aldersgrupper. 
Informasjon om inntak av folsyre fra berikede matvarer er ikke tilgjengelig. I følge en norsk 
modell for vurdering av berikning fra 2006 med senere oppdateringer (sist oppdatert i 2013), 
kan det tilsettes 53 µg folsyre per 100 kcal mat og/eller drikke uten at det vil føre til 
overskridelse av UL for folsyre i noen aldersgrupper. Med dagens nivåer i kosttilskudd og 
dagens nivåer i berikede produkter vil ikke UL for folsyre overskrides. 
VKM ble også bedt om å vurdere konsekvensene av en eventuell økning av gjeldende 
maksimumsgrense på 200 µg for folsyre i kosttilskudd. Dersom maksimumsgrensene økes til 
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400 µg, vil det kunne medføre en overskridelse av UL for barn under 6 år, og et inntak tett 
opp til UL for barn i aldersgruppen 7 - 10 år. Dersom maksimumsgrensene for folsyre i 
kosttilskudd økes til 600 µg, vil det kunne medføre en overskridelse av UL for barn under 
10 år og tett opp til UL for barn 11 - 14 år. En økning av maksimumsgrensen for folsyre i 
kosttilskudd til 400 µg eller 600 µg vil ikke medføre en overskridelse av UL for den voksne 
befolkningen. Disse beregningene er basert på den norske modellen for vurdering av 
berikningssaker (VKM, 2013). 
Det er altså ikke vist noen sikker sammenheng mellom folsyretilskudd og kreft i den 
gjennomgåtte litteraturen. Folsyretilskudd er gitt til pasienter som på forhånd var behandlet 
for tykktarmsadenomer. Hos denne gruppen, som anses som ekstra sårbar for utvikling av 
kreft, fant man ingen økt risiko for tykktarmskreft eller nye adenomer i tykktarmen etter 3 -5 
års behandling med 1000 µg folsyre per dag. Derfor konkluderer VKM med at studier som 
har undersøkt sammenhengen folsyre og kreft etter 2009 og fram til oktober 2014 ikke gir 
grunnlag for å endre eksisterende UL for folsyre. 
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Abbreviations and glossary 
5-MTHF – 5-methyl tetra hydrofolate 
CI  – confidence interval 
CNS  – central nervous system 
CVD  – cardiovascular disease 
DR  – dietary reference value 
EAR  – estimated average requirement (EAR+2SD=recommended intake) 
EFSA  – European Food Safety Authority 
ESCO  – EFSA Scientific Cooperation Working Group 
FFQ  – food frequency questionnaire 
HR  – hazard ratio 
IOM  – Institute of medicine 
IQR  – interquartile range 
LOAEL  – lowest observed adverse effect level 
MoBa  – The Norwegian Mother and Child cohort study 
NHANES – National Health and Nutrition Examination Survey 
NNR  – Nordic nutrition recommendations 
NOAEL  – no observed adverse effect level 
NTD  – neural tube defect 
OR  – odds ratio 
RCT  – randomised controlled trial 
RBC  – red blood cell 
RR  – risk ratio or relative risk 
SAM  – S-adenosylmethionine 
SC   – Scientific Committee on Food 
SD  – standard deviation 
THF  – tetra hydrofolate 
UL  – tolerable upper intake level 
UMFA  – unmetabolised folic acid 
VKM  – Norwegian Scientific Committee For Food Safety 
Primary prevention trial – study investigating delay or prevention of onset of a disease or 
condition. 
Secondary prevention trial – study investigating subjects with a disease or condition to 
prevent recurrence or exacerbation. 
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Background as provided by the 
Norwegian Food Safety Authority/ 
Norwegian Environment Agency 
Directive 2002/46/EC on food supplements was implemented in Norwegian law in 2004 in 
Regulation 20 May 2004 No. 755 on food supplements. Pursuant to Directive 2002/46/EC, 
common maximum and minimum levels of vitamins and minerals in food supplements shall 
be set. 
National maximum limits for vitamins and minerals were established in the former regulation 
on vitamin and mineral supplements from 1986 and were continued in the 2004 regulation. 
These maximum limits apply until common limits are established in the EU. 
The European Commission started to establish common limits in 2006, but the work was 
temporarily put on standstill in 2009. The time frame for the further work is not known.  
Maximum limits for levels of vitamins and minerals in food supplements shall be set on the 
basis of the following criteria, pursuant to article 5 in Directive 2002/46/EC:  
• Upper safe levels of vitamins and minerals established by scientific risk assessment 
based on generally accepted scientific data, taking into account, as appropriate, the 
varying degrees of sensitivity of different consumer groups  
• Intake of vitamins and minerals from other dietary sources 
When the maximum levels are set, due account should also be taken of reference intakes of 
vitamins and minerals for the population. 
Pending establishment of common maximums limits in the EU, the Norwegian Food Safety 
Authority is evaluating the national maximum limits for vitamins and minerals in food 
supplements. 
The Norwegian Food Safety Authority is currently evaluating the national maximum limit for 
folic acid, considering the criteria listed above. 
Pursuant to the Norwegian regulation on food supplements, the minimum and maximum 
limit for folic acid in food supplements is 25 µg and 200 µg per daily dose, respectively. 
Exemptions for using 400 µg folic acid per daily dose have been given provided certain 
labelling requirements are fulfilled. The exemptions are based on a recommendation issued 
by the Norwegian Directorate of Health, saying that women who might become pregnant 
should supplement their diet with 400 µg folic acid per day. 
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Pursuant to the food supplement regulation, only one form of folic acid may be used in food 
supplements; pteroylmonoglutamic acid. Also calcium-L-methylfolate may be used in food 
supplements as a folate source. The terms of reference in this opinion addresses only folic 
acid. 
Relevant background documents  
1. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level on 
Folate (SCF, 2000) 
2. Folic acid: An update on scientific developments (EFSA, 2010) 
3. ESCO report on Analysis of Risks and Benefits of Fortification of Food with Folic Acid 
(EFSA, 2009) 
4. Cancer incidence and mortality after treatment with folic acid and vitamin B12 (Ebbing et 
al., 2009) 
5. Safe Upper Levels for Vitamins and Minerals, UK (EVM, 2003) 
6. A safe strategy for addition of vitamins and minerals to foods (Rasmussen et al., 2006) 
Terms of reference as provided by the 
Norwegian Food Safety Authority/ 
Norwegian Environment Agency 
The Norwegian Food Safety Authority requests the Norwegian Scientific Committee for Food 
Safety (VKM) to assess the risk of folic acid in food supplements. The risk assessment should 
address the following aspects and questions: 
1. In 2000, the Scientific Committee on Food (SCF) set a tolerable upper intake level (UL) 
for folic acid of 1 mg/day for adults. ULs for adolescents and children were adjusted 
downwards on the basis of body weight. Subsequently, new scientific evidence has 
emerged suggesting a possible link between high intake levels of folic acid and risk of 
cancer (Ebbing et al., 2009; EFSA, 2009). In the light of the latest scientific data on 
folic acid, should the UL be amended?  
2. It is important to ensure that the total intake of vitamins and minerals from all sources 
does not exceed the UL. However, folic acid is the synthetic form of the vitamin 
which is not found naturally in foods. VKM is therefore requested to estimate the 
intake of folic acid from food supplements and foods that are added folic acid, in all 
age groups in the population above 1 year. 
3. VKM is requested to elucidate the consequence of amending the maximum limit for folic 
acid in food supplements for the total intake of folic acid (from food supplements and 
foods added folic acid). 
 








Folic acid supplementation and fortification of food with folic acid have substantially reduced 
the incidence of neural tube defects (NTD)(Botto et al., 2005; Williams et al., 2002). 
However, there are indications that high intake of folic acid may increase the risk of cancer, 
cause cognitive decline in susceptible populations, and result in epigenetic changes (Cole et 
al., 2007; Ebbing et al., 2009; Kim et al., 2001). 
Folic acid is a synthetic form of folate and is commonly used in food supplements and in food 
fortification because of its stability and bioavailability. In Norway, food fortification is not 
mandatory and foods that are fortified with folic acid do not contribute much to the total 
intake of folic acid. Folic acid supplementation has been recommended before and during 
early pregnancy from 1998 but despite of this only 19.8% of the women participating in the 
Norwegian Mother and Child Cohort study used folic acid supplementation one month before 
becoming pregnant and less than half of the women used folic acid supplements at 
gestational month three (Nilsen et al., 2006). 
Possible negative health effects from high intakes of folic acid have previously been 
evaluated by the Scientific Committee for Food (SCF, 2000), Institute of Medicine (IOM, 
2000), Nordic Nutrition Recommendations (NNR Project Group, 2012) and European Food 
Safety Authority (EFSA, 2009; EFSA, 2014). 
With intakes of more than 200 µg folic acid unmetabolised folic acid (UMFA) has been 
recovered in the circulation (Kelly et al., 1997). It has been postulated that UMFA could 
affect homeostatic regulation of folate (Smith et al., 2008), and reduce natural-killer cell 
cytotoxicity, which raises the question about UMFA and cancer risk (Troen et al., 2006).  
Recently, EFSA published Dietary Reference Values (DRVs) for folate (EFSA, 2014). EFSA 
states that natural food folates are safe and high intakes have not been associated with any 
adverse effects. The aim of this report is therefore to evaluate the Tolerable Upper Intake 
Level for supplemental folic acid. 
Adverse effect of folic acid supplementation and/or fortification has so far been reported on 
cancer development. Therefore and in accordance with terms of reference, cancer 
development is the evaluated outcome in this report.  
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2 Hazard identification and 
characterisation 
2.1 Chemistry, absorption and metabolism 
Chemistry 
Folates encompass several forms of the vitamin which are different with regard to stability 
and bioavailability. We use the term “folic acid” for the most commonly occurring synthetic 
form and “folate” for the folates naturally found in foods. Folic acid and folates comprise an 
aromatic pteridine ring linked to a p-aminobenzoic acid and at least one glutamate residue 
(Figure 2.1-1). About half of the folate in the body is stored in the liver. 
 
Figure 2.1-1 Structural form folic acid. 
Function 
Folate is cofactor for enzymes in one-carbon metabolism, where it provides one-carbon units 
for the formation of RNA and DNA. Folate is also essential for the normal functioning of the 
methionine cycle, which is responsible for both the conversion of homocysteine to 
methionine and the production of the universal methyl donor S-adenosylmethionine (SAM). 
SAM donates its methyl group to more than 100 methyltransferases for a wide range of 
substrates such as DNA, hormones, proteins, neurotransmitters and membrane 
phospholipids.  
Occurrence and recommendations 
Folate is present in most foods. High concentrations are found in liver, green vegetables and 
legumes. The most important food groups contributing to folate intake are whole grain 
cereals and vegetables, however, dairy products, fruits and berries are also important 
sources. Based on losses through urine and the enterohepatic circulation in well-nourished 
individuals, the estimated average requirement of folate is set to 200 μg/day and 
recommended intake to 300 μg/day. For children 6 to 9 years the recommended intake is 
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130 μg/day and for children and adolescents aged 10 to 13 years 200 μg/day. For women in 
reproductive ages supplementation of 400 μg/day is recommended in addition to foods rich 
in folate since there is convincing evidence that an adequate supply of folate before and up 
to 12 weeks after conception reduces the risk of NTD. To ensure folate intake during 
pregnancy, women are recommended to take a folic acid supplement one month before 
conception and during the first three months into pregnancy to reduce the risk of NTD 
(Czeizel and Dudas, 1992; ernæringsråd, 1997; Tell et al., 1998). 
Intake and folate status 
According to Norwegian dietary surveys the mean dietary intake of folate is within the 
estimated average requirement (EAR), but does not reach the recommended intake 
(NORKOST 3; mean intake 279 μg/day (SD 105) for men and 231 μg/day (SD 86) in 
women). No information about folate intake is available for children and adolescents. 
However, in 2-year old Norwegian children, the median folate intake from food was 
87 µg/day (IQR: 74-106) and the median plasma folate concentration was 19 nmol/L (IQR 
14-24) (Hay et al., 2011). The Panel on Dietetic Products, Nutrition and Allergy (NDA) in the 
European Food Safety Authority (EFSA) considered that the previously defined cut offs for an 
adequate folate status are still suitable for determining folate requirement (for serum folate 
10 nmol/L and for red blood cell folate of 340 nmol/L) (EFSA, 2014). Data from Norway 
indicate that the mean value of serum folate was below the value considered adequate by 
EFSA (Dhonukshe-Rutten et al., 2009) and in pregnant women only those using regular folic 
acid supplementation reached an adequate folate status (Bjorke-Monsen et al., 2013). 
Absorption and metabolism 
Natural folates rapidly lose activity in foods during harvesting, storage and preparation and 
up to 75% of folate activity may be lost before ingestion, while folic acid is almost 
completely stable for months or even years (EFSA, 2014). Folic acid is readily absorbed, but 
has to be reduced (or “metabolised”) before it can enter the metabolic pathway. For 
naturally occurring folates, one or more glutamate residues have to be removed before 
absorption can occur. The absorption of folate and the conversion of folic acid have both 
limited capacity. Excess natural folate may accordingly result in a lower fraction absorbed 
and excess folic acid may result in unmetabolised folic acid in the circulation. Virtually all 
folate in plasma is of the reduced and methylated form 5-methyl tetra hydrofolate (5-MHTF). 
This is also a form that can donate one-carbon units in metabolic processes. 
There is evidence that circulating unmetabolised folic acid impairs natural killer cell function 
and cell-mediated toxicity. Cell-mediated immunity may be important in the protection 
against the formation of malignant tumors and cancer development. A recent in vitro study 
using breast cancer cell lines also demonstrated a dose dependent relationship between 
down-regulation of tumor suppressor genes and folic acid concentration, suggesting an 
alternate mechanism whereby folic acid could contribute to tumor formation (Lubecka-
Pietruszewska et al., 2013). Results from large, randomised placebo controlled trials with 
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folic acid supplementation also indicate that folic acid may increase cancer risk (Bonaa et al., 
2006; Cole et al., 2007; Ebbing et al., 2009). 
Folate deficiency and high intakes 
The predominant feature of folate deficiency is megaloblastic anemia (SCF, 2000). Folates 
and vitamin B12 share metabolic pathways and are important for DNA and protein synthesis 
and therefore cell growth and differentiation. Poor intake of either folate or vitamin B12 often 
has similar health consequences such as anemia. A high intake of folic acid may mask some 
of the early symptoms of vitamin B12 deficiency. Vitamin B12 deficiency may lead to 
neurological dysfunction and decline in cognitive function, which in some cases are 
irreversible. Intake of natural folate has so far not been found to mask vitamin B12 
deficiency. Knowledge built on folic acid supplementation in B12 deficient subjects resulted in 
an Upper Tolerable Intake Level (UL) of 1 mg of folic acid per day, set by the Scientific 
Committee on Food (SCF) in 2000 (SCF, 2000). 
2.2 Mechanisms for cancer development 
As mentioned above, unmetabolised folic acid can attenuate natural killer cell cytotoxicity 
which is an important part of the nonspecific immune response. In vitro studies have also 
demonstrated that folic acid can down-regulate tumor suppressor genes (Lubecka-
Pietruszewska et al., 2013). 
Folates are important for cell division. It is therefore possible that tumor growth or growth of 
premalignant cells may be stimulated by high concentrations of folate in the blood. Many 
cytostatic drugs target folate metabolism in order to reduce tumor growth. It is possible that 
folate plays a dual role in carcinogenesis; prevention of early lesions but enhancing growth 
once preneoplastic lesions have developed.  
2.3 Previous reports on UL for folic acid 
Possible negative health effects from high intakes of folic acid have previously been 
evaluated by several international bodies. Main findings from these are presented below. In 
several publications the terms "folate" and "folic acid" are used inaccurately. In the following 
sections, we have used the same terminology as those used in the reports that are reviewed. 
2.3.1 Scientific Committee on Food, 2000 
The Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of folic 
acid was published in 2000 by the Scientific Committee on Food (SCF) under the Health and 
Consumer Protection Directorate – General of the European Commission (SCF, 2000). 
This report discusses the various forms of folate and the potential risks of high intake as well 
as the risks involved by folic acid supplementation/fortification.  
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Potential health risks are discussed in light of the estimated folate intake in five countries 
(Austria, Germany, Ireland, Italy and the Netherlands). The intake in Europe is remarkably 
similar across different countries, and seemingly adequate except in women with a wish to 
become pregnant. The recommended intake of folate among women planning for pregnancy 
is 400 µg per day, however, >90% of women in the childbearing age had an intake lower 
than this.  
The ”nutritional background” of the report focuses on differences between naturally 
occurring folates in foods versus the synthetic folic acid found in supplements and fortified 
food. Folic acid, which is an oxidised folate, is more stable and more readily absorbed than 
naturally occurring folates.  
Potential adverse effects of folic acid supplementation:  
1. modification of vitamin B12 deficiency symptoms due to folic acid  supplementation:  
a. masking of hematological symptoms,  
b. exacerbation of neurological symptoms;  
2. epileptogenic and neurotoxic effects of folic acid; 
3. decreased efficacy of folate antagonists used in chemotherapy; 
4. carcinogenicity 
Vitamin B12 deficiency and neurotoxicity. Folate and vitamin B12 share metabolic 
pathways and are important for DNA and protein synthesis and therefore cell growth and 
differentiation. Deficiencies of both vitamins result in macrocytic anemia. A high intake of 
folic acid can delay the onset of macrocytic anemia caused by vitamin B12 deficiency and 
accordingly mask the symptoms of B12 deficiency. Vitamin B12 is important for brain function 
and for the developing nervous system and deficiency has been associated with decreased 
cognitive performance and neurological manifestations. There are indications that folic acid 
in high doses has a neurotoxic effect particularly among vitamin B12 deficient individuals. 
Results from the studies suggesting that folic acid supplementation mask B12 deficiency 
and/or has a neurotoxic effect are conflicting, small, use high doses of folic acid (5-100 mg 
daily), and are old (> 50-60 years). More recent reviews have concluded that there is no 
convincing harmful effect on the central nervous system (CNS) of folic acid, even in 
individuals who are vitamin B12 deficient.  
Antifolate drugs, such as methotrexate, are commonly used and folates may potentially 
attenuate the effect of these. To what extent folic acid supplementation modifies the effects 
of these drugs is not clear.  
Cancer. Intake of folic acid is positively associated with some cancers, but adequate folate 
status may also protect against other cancers. 
The report concludes as follows:“Although no systematic toxicological studies of folic acid or 
other folates are available, an upper safe level can be set for folic acid on the basis of 
findings in vitamin B12 deficient patients treated with high doses of folic acid. There is no 
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evidence for risk associated with high intakes of natural, reduced folates, and thus no data 
to set an upper limit for natural folate. Although there is no conclusive evidence in humans, 
the Committee concluded that the risk of progression of the neurological symptoms in 
vitamin B12-deficient patients as a result of folic acid supplementation cannot be excluded 
and should be considered the most serious adverse effect. In nearly all studies showing 
neurological relapse, dose levels >5 mg folic acid per day have been applied and data on the 
effect of dose levels between 1-5 mg is limited to a few cases.” 
In analogy with the US DRI Committee, it is concluded that the best available estimate for a 
lowest-observed-adverse-effect level (LOAEL), obtained from a sensitive group, for folic acid 
is 5 mg, and as dosages up to 1 mg of folic acid are unlikely to cause masking of the 
hematological signs in patients with pernicious anemia, the UL is set at 1 mg of folic acid.”  
Suggested ULs for folic acid from SCF is given in Table 2.3.1-1. 
Table 2.3.1-1 ULs for folic acid in SCF, 2000 in µg/day. 







The SCF report recommended more research on the effects of high folate on the 
”symptomatology of vitamin B12 deficiency”, and the risk of folic acid supplementation in 
populations where vitamin B12 deficiency is prevalent. They also recommended studies on 
the safety and efficacy of other synthetic folates. 
2.3.2 Institute of Medicine, 2000 
In 2000, the United States Institute of Medicine (IOM) published an evaluation of UL for 
folate (IOM, 2000). No observations of adverse effects of high intake of folate (dietary) from 
traditional foods or fortified foods were found, and the evaluation is limited to evidence 
concerning intake of supplemented folic acid. In the hazard identification chapter, the IOM 
describes the association between high doses of folic acid that may correct megaloblastic 
anemia. At the same time it may mask vitamin B12 deficiency and the neurological damage 
may not be diagnosed until these neurological consequences have become irreversible. High 
doses of folic acid could precipitate or exacerbate the anemia and cognitive symptoms 
associated with vitamin B12 deficiency, perhaps by increasing homocysteine or methylmalonic 
acid concentrations. However, the high homocysteine and methylmalonic acid concentrations 
in people with low vitamin B12 and high folate concentrations could be due to severe 
malabsorptive conditions or pernicious anemia rather than high folic acid intakes. The high 
folate concentrations in vitamin B12 deficient individuals are probably due to the folate trap 
 
VKM Report 2015: 05  21 
 
mechanism. Neurological effects are mostly seen in B12 deficient subjects, such as older 
persons and those adhering to a vegan diet. 
Concerns were raised that high folic acid supplementation might accelerate the progression 
of preneoplastic lesions, increasing the risk of colorectal and possibly other forms of cancer 
in certain individuals.  
Based on the metabolic interactions between folate and vitamin B12, IOM established a UL for 
adults, pregnant and lactating women for the synthetic forms of folate (i.e., folic acid) 
available in dietary supplements and fortified foods. The UL for infants and children were 
adjusted from the adult value on the basis of relative body weight. The ULs do not apply to 
individuals taking high doses of folic acid under medical supervision. Suggested ULs for folic 
acid from the IOM is provided in Table 2.3.2-1. 
Table 2.3.2-1 ULs for folic acid in IOM (2000) in µg/day. 
Age Men Women Pregnancy Lactation 
Birth to 6 months Not possible to 
establish* 
Not possible to 
establish* 
  
7-12 months Not possible to 
establish* 
Not possible to 
establish* 
  
1-3 years 300 300   
4-8 years 400 400    
9-13 years 600 600   
14-18 years 800 800 800 800 
19+ years 1000 1000 1000 1000 
*Breastmilk, formula, and food should be the only sources of folate for infants. 
2.3.3 ESCO Working Group (EFSA), 2009 
The ESCO Report from Analysis of Risks and Benefits of Fortification of Food with Folic Acid 
(2009) was prepared by the EFSA Scientific Cooperation Working Group on Analysis of Risks 
and Benefits of Fortification of Food with Folic Acid (EFSA, 2009). 
The EFSA Scientific Cooperation Working Group (ESCO WG) on “Analysis of risks and 
benefits of fortification of food with folic acid” was established by EFSA in 2008. The group 
was asked to i) review current practice in the Member States regarding the level of voluntary 
fortification of foods with folic acid and ii) consider new evidence regarding the risk of high 
intakes of folic acid and the need to review current guidance on safe upper levels of folic 
acid for all population groups. 
The ESCO report concluded that the beneficial effect of folic acid in reducing the risk of NTDs 
was well established.  
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Prevalence of NTD-affected pregnancies ranges from 4.1 to 19.7 per 10 000 births. Parts of 
this variation can be explained by different methods of data collection and reporting.  
Although suggestions for additional beneficial effects of folic acid supplementation including 
reduction in cardiovascular disease (CVD), cancer and cognitive decline have been made, 
evidence for such benefits has so far not been supported by randomised controlled trials 
(RCTs). 
National recommendations/reference values for folate intake varied across the European 
countries from 200 µg to 400 µg folate per day for adults. A recommendation of an 
additional 400 µg per day was recommended for women of childbearing age/planning a 
pregnancy. 
Available data indicate that across European countries, the average dietary folate intake 
ranges from 151 to 345 µg/day for men and from 122 to 339 µg/day for women. Average 
intake of folate from diet and supplements ranges from 338 to 385 µg/day for men and from 
220 to 478 µg/day for women. No European country had introduced mandatory fortification. 
The report also underlined the importance of distinguishing between different sources of folic 
acid (from supplements and fortified foods) as pharmacokinetics may vary depending on 
form and dosage. 
Available animal studies suggested a possible association between high intakes of folic acid 
and promotion of cancer development and progression. A study from USA and Canada 
suggested that colorectal cancer incidence increased at around the same time that 
mandatory fortification with folic acid was introduced. 
The totality of evidence from RCTs up to the date of the ESCO report did not suggest that 
folic acid intakes were associated with increased cancer risk. The report stressed however 
that the interpretation of the data from the available studies were limited by a number of 
issues including the duration of the trials and limited power of the meta-analyses. 
In the ESCO report it was concluded that intakes of folic acid should not exceed the 
established UL of 1 mg/day (SCF, 2000). The UL was based on limited data. If further data 
become available, it was underlined that UL needed to be discussed further. 
2.3.4 EFSA meeting summary report 
EFSA and the Swedish National Food Administration organised a scientific meeting on “Folic 
Acid: An update on Scientific Developments” in Uppsala, Sweden on 21-22 January 2009 
(EFSA, 2010). The aim of the meeting was to consider the evidence regarding folic acid and 
cancer risks, including cancer of the colon, breast and prostate. 
Scientific evidence concerning folate metabolism, animal and mechanistic studies and human 
studies was reviewed and discussed. The experts should consider if it was possible to 
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identify an association of folic acid intake with risk of cancer and whether the available data 
were sufficient to allow quantitative risk assessment. The conclusions from the meeting 
were: 
• There was a disagreement between experts regarding the interpretation of the trial 
evidence. The UL of 1 mg/day, which is based on limited data, may need to be revised when 
further data become available. 
• There are currently insufficient data to allow a full quantitative risk assessment of folic acid 
and cancer or to determine whether there is a dose-response relationship or a threshold 
level of folic acid intake associated with potential colorectal cancer risk. 
• The current evidence does not show an association between high folic acid intakes and 
cancer risk, but neither do they confidently exclude a risk. 
• It is important to distinguish between different sources of folate, i.e. natural food folate 
and folic acid from fortified foods and from supplements.  
• Setting maximum safe levels for the amount of folic acid that can be added to foods 
voluntarily fortified with folic acid and supplements will be important in ensuring that 
consumption of foods fortified with folic acid and folic acid supplements does not lead to 
intakes above the UL. 
2.3.5 Nordic Nutrition Recommendations 5th edition, 2012 
In the Nordic Nutrition Recommendations (NNR) from 2012 it is stated that there is no 
evidence for adverse health effects associated with high intakes of folate from natural 
sources, but high intake of folic acid can mask hematological symptoms caused by deficiency 
of vitamin B12 (NNR Project Group, 2012). Suggested ULs for folic acid from NNR is given in 
Table 2.3.5-1. 
Table 2.3.5-1 ULs for folic acid from NNR (2012) in µg/day. 
Age Men/Women Pregnancy Lactation 
1-3 years 200   
4-6 years 300   
7-10 years 400   
11-14 years 600    
15-17 years 800   
18 + years 1000 1000 1000 
2.3.6 Dietary reference value (DRV) EFSA, 2014 
Recently, EFSA published Dietary Reference Values (DRVs) for folate (EFSA, 2014). In this 
opinion, EFSA states that natural folates are safe and that high intakes have not been 
associated with any adverse effects (SCF, 2000). The Tolerable Upper Intake Level (UL) was 
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set by SCF based on safety concerns for high intake of the synthetic form of the vitamin, i.e. 
folic acid and its ability to mask vitamin B12 deficiency by reversing megaloblastic anemia. In 
this way high folic acid intake may allow the neurological dysfunction of B12 deficiency to 
progress to irreversible subacute degeneration of the spinal cord. To set the UL it is referred 
to the SCF report of 2000 i.e. UL to 1000 µg per day for adults and ranging from 200 μg/day 
(1-3 years) to 800 μg/day (15-17 years).  
The importance of folic acid as protective or as enhancing in cancer development was further 
discussed referring to observational studies which have suggested that folic acid supplement 
use was inversely associated with cancer incidence (Ericson et al., 2007; Giovannucci et al., 
1998). However, safety concerns were expressed with the publication of two studies 
suggesting that chronic ingestion of folic acid at doses of 1 mg/day or above might increase 
the risk of colorectal neoplasia in individuals with a recent history of colorectal adenomas 
(Cole et al., 2007) or increase the risk of development of prostate cancer, stimulating 
proliferation of already established neoplastic foci in the colorectal mucosa (Kim, 2004). The 
EFSA Panel further refers to the meta-analyses of Vollset et al. (2013) and to Mackerras et 
al. (2014) showing that folic acid supplementation at a median dose of 2 mg/day and 
administered with or without other B-vitamins for an average duration of 5.2 and 7.3 years 
did not significantly increase the overall or site-specific cancer incidence compared with 
placebo. The EFSA Panel notes that the follow-up period of the trials included in these meta-
analyses were rather short considering the development of cancer. Thus, the question of the 
relationship between folic acid and cancer requires to be clarified by studies designed with 
sufficiently long follow-up periods addressing the biological hypothesis for the dual effect of 
folic acid on cancer development (EFSA, 2009).  
Concerns were also raised regarding the potential adverse effects associated with the 
presence of unmetabolised folic acid in the circulation. Three studies from Europe (Boilson et 
al., 2012; Obeid et al., 2010; Sweeney et al., 2009) and a nationally representative study 
from the US (Bailey et al., 2010) reported that a considerable proportion (40-90%) of the 
investigated populations exposed to fortified foods and involving both supplement and non-
supplement users had a detectable concentration of unmetabolised folic acid in the blood 
even in fasting conditions. The metabolic and biological consequences of the presence of 
unmetabolised folic acid in the circulation are as yet uncertain (Morris et al., 2010; Troen et 
al., 2006). 
2.3.7 Summary previous reports on folic acid 
The main adverse effects of folic acid discussed in the above mentioned reports are masking 
of vitamin B12 deficiency and potential adverse effects on cancer development. 
All the reports agree with the Tolerable Upper Intake Level (UL) for folic acid established by 
SCF in 2000, for adults at 1 mg/day. High intake of folic acid may correct megaloblastic 
anemia, which is the hallmark symptom of vitamin B12 deficiency. Folic acid masks vitamin 
B12 deficiency by reversing megaloblastic anemia and in this way allows the neurological 
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dysfunction of vitamin B12 deficiency to progress. Neurological damage may not be 
diagnosed until the neurological consequences have become irreversible.  
A lowest-observed-adverse-effect level (LOAEL) was set at 5 mg per day. As dosages up to 
1 mg of folic acid are unlikely to cause masking of the hematological signs in patients with 
pernicious anemia, the UL was set at 1 mg of folic acid.  
The ULs for children and adolescents (1-17 years) are adjusted on the basis of body weight 
and range from 200 to 800 μg/day. 
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2.4 Literature search 
A literature search was conducted in order to assess updated knowledge about cancer 
development related to high intakes of supplemental folic acid. The search aimed to retrieve 
studies addressing high intakes of folic acid in food supplements. 
2.4.1 Search strategy 
In order to retrieve relevant publications addressing high intakes of supplementary folic acid 
and cancer, literature searches in MEDLINE and EMBASE were conducted (3 September 
2014). Both databases were used to ensure comprehensive study retrieval. The strategy for 
the searches was discussed within the project group. 
The search included the terms folic acid supplement and cancer. Only human studies were 
included. The search terms used are presented in Appendix I. 
The search period was limited to publications from 2009 to today as older relevant literature 
was expected to be covered in the comprehensive ESCO-report from 2009. The search was 
further limited to include publications written in English, Danish, Swedish or Norwegian. 
An additional search was conducted in MEDLINE 15 October 2014 to identify specifically 
RCTs published after 2009. The search included the term folic acid (in title) and was limited 
to only RCTs in addition to language limitations. For view of the search terms used, see to 
Appendix I. 
2.4.2 Publication selection 
The study types for inclusion in this opinion were systematic reviews and meta-analyses of 
human studies, RCTs and prospective studies with data on folic acid supplementation in at 
least one group. The criteria for inclusion were: 
• Folic acid in relation to health outcome was the main issue (or one of the main 
issues) in the article 
• Results for folic acid could be separated from results from other interventions e.g. 
supplements from other B-vitamins 
• The results for folic acid supplementation could be compared to a placebo group 
In vitro studies were excluded from the results in this opinion. Position papers, conference 
abstracts/summaries, editorial comments and various dietary guidelines were excluded. 
Additionally, studies were excluded if the result could be affected by other vitamins. 
The literature searches in September 2014 identified 88 articles in MEDLINE and 44 in 
EMBASE (duplicates not excluded). The additional MEDLINE search in October 2014 
identified 100 articles. 
 
VKM Report 2015: 05  27 
 
Study titles and abstracts were reviewed by two persons of the project group according to 
the above mentioned inclusion criteria. Titles were selected if chosen by one of the experts, 
and resulted in 35 full text articles which were distributed in the project group for full text 
examination. This resulted in the inclusion of 17 studies. Additionally, two studies from hand 
searching/retrieval of relevant literature cited in the full-text papers have been identified and 
are included. 
A final total of 19 publications were identified and included in the results in this report (see 
Figure 2.3.2-1).  
Figure 2.3.2-1 Flowchart for the literature search for supplementary folic acid and associated health 
outcomes and the subsequent selection of publications. 
2.4.3 Data extraction, relevance and quality assessment 
Several of the studies retrieved in the literature search were studies investigating possible 
beneficial effects of folic acid on cardiovascular diseases or prevention of other conditions. 
The study design of these "effect"-studies might not be suitable for detecting increased 
incidence of cancer, but are however the best at hand. 
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Relevance for the purpose of this opinion has been evaluated for each included paper, and is 
stated in the Summary Tables in Appendix III. 
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2.5 Human studies published after 2009 investigating 
supplementary folic acid in relation to cancer 
This chapter includes a brief description of the studies included in this opinion. Only studies 
investigating outcomes related to cancer have been included. 
2.5.1 RCTs and case-control studies 
A list of excluded papers can be found in Appendix II. An overview of RCTs and case control 
studies included in this report is given in Table 2.5.1-1. 
Table 2.5.1-1 Overview of RCTs and case-control studies with folic acid reporting cancer. 
Reference RCT Study design Participant 
characteristics 




Gao et al. 
(2013) 
RCT. 384 in 
treatment 
group and 407 
in control group 
Healthy above 
50y, both sexes.  
China 1 mg Adenoma 3y Unadjusted RR 
0.49 
(0.37,0.63) 





group and 334 
placebo group 
Patients with a 
history of 
adenoma 
USA 1 mg Adenoma 3-6.5y RR 0.82 
(0.59,1.13) 
Figueiredo et al. 
(2009) 
Secondary 
analysis of RCT. 
237 treatment 
group and 235 
placebo group 
Patients with a 
history of 
adenoma 
USA 1 mg Prostate 
cancer 
Median 7 y (up 
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Gao et al., 2013 (adenoma) 
In an RCT by Gao et al. (2013), 791 healthy Chinese older than 50 years were randomised to 
receive 1 mg folic acid or a multivitamin tablet not containing folic acid. The participants 
were followed for three years. The folic acid group was requested to visit their doctor every 
three months while the control group was contacted by mail or phone. All had a colonoscopy 
on the final day of the study.  
The occurrence of colorectal adenomas was compared between the two groups. Colorectal 
adenomas occurred in 64 (14.88%) in the folic acid group and 132 (30.70%) in the control 
group (unadjusted RR 0.49; 95% CI, 0.37-0.63). The risk of more advanced adenomas was 
also significantly and substantially reduced in the group receiving folic acid. 
This study indicate that primary prevention with 1 mg/day folic acid supplementation could 
reduce the incidence of colorectal adenomas, especially left-sided and advanced disease in 
those with no previous adenomas. 
However, this study suffers from somewhat poor design such as being unblinded, different 
follow-up procedures in the two groups, and it did not include a placebo but compared folic 
acid supplementation to a multivitamin tablet. 
Wu et al., 2009 (adenoma) 
A cost-effective randomised placebo controlled trial was nested within two ongoing cohort 
studies (the Health Professionals Follow-Up study and the Nurses’ Health study) by Wu et al. 
(2009). Participants who had a history of colorectal adenoma, were cancer free, and who 
planned to have another endoscopy within the next four years, were found eligible for 
enrollment. The participants were randomised to receive 1 mg of folic acid or placebo for 3 
to 6.5 years (n=672). 
Incidence of at least one recurrent adenoma was not significantly associated with folic acid 
supplementation. Among participants with low plasma folate concentrations at baseline 
(<7.5 ng/mL), those randomly assigned to receive folic acid experienced a significant 
decrease in adenoma recurrence (RR: 0.61; 95% CI: 0.42, 0.90), whereas for subjects with 
high folate concentrations at baseline (7.5 ng/mL), supplemental folic acid had no significant 
effect (RR 1.28; 95% CI: 0.82, 1.99, P-interaction=0.01). 
There was no evidence for an increased risk of advanced or multiple adenomas. On the 
contrary, in individuals with poor folate status the risk of cancer was reduced. 
Figueiredo et al., 2009 (prostate cancer) 
Figueiredo et al. (2009) analysed to what extent supplementation of 1 mg of folic acid 
increased the risk of prostate cancer using data from a previously published RCT (Cole et al., 
2007). The trial was carried out between 1994 and 2006 and the analyses included 643 men 
who had been randomised to receive folic acid or placebo. The participants were followed up 
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for a median of 7 years, maximum 10 years. The outcome, prostate cancer, was ascertained 
from medical reports and included reports of histopathology. 
Cox proportional hazards models were used to estimate the association between baseline 
vitamin B status and prostate cancer and the effect of folic acid supplementation on prostate 
cancer. 
Intake of folate and folic acid from the diet were similar in the two groups, as were plasma 
concentration of folate and unmetabolised folic acid (UMFA). However, the folic acid 
supplemented group had a lower vitamin B12 status at inclusion. 
Folic acid supplementation was associated with an increased risk of prostate cancer (hazard 
ratio (HR) 2.63; 95% CI 1.23-5.65). Plasma folate concentration in the non-supplemented 
group was inversely associated with the risk of prostate cancer (borderline significant). 
This secondary analysis demonstrated that folic acid supplementation and poor folate status 
was associated with an increased risk of prostate cancer. A small number of prostate cancer 
cases made the result not robust. 
Milne et al., 2012 (brain tumor) 
In a case control study by Milne et al. (2012) the aim was to measure to what extent pre- 
pregnancy or pregnancy folic acid supplementation alone or with other supplements was 
associated with childhood brain tumors. The study included 327 cases of brain tumors from 
10 Australian pediatric oncology centers between 2005 and 2010. The 867 controls were 
selected randomly. The cases and controls were between 0 and 14 years. The 
parents/guardians were mailed questionnaires with questions on folic acid supplements or 
intake of other vitamins before and/or during pregnancy, specified by trimester. Intake of 
folic acid was categorised in three groups; 0.1-300 µg, 300-450 µg and >450 µg folic acid. 
Non-compliers were contacted by phone.  
The association between folic acid and brain tumors was estimated in multiple, unconditional 
regression analyses. The exposure variables were whether or not folic acid was taken in pre-
pregnancy, during the first trimester or during the last two trimesters of pregnancy. A dose 
response relation between folic acid and risk of cancer was also estimated. 
Pre-pregnancy supplementation of folic acid was associated with a significant reduction in 
the odds of childhood brain tumor (OR 0.65; 95% CI 0.43-0.98). The effect of folic acid 
during pregnancy was lower and did not reach statistical significance. The effect of providing 
other vitamins or minerals was much less clear and did not attain statistical significance. This 
study shows that folic acid before or during early pregnancy reduces the risk of childhood 
tumors. It should be noted that these tumors are very rare. 
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Amigou et al., 2012 (leukemia) 
In a case-control study by Amigou et al. (2012) the authors measured the association 
between maternal folic acid supplementation before and during pregnancy and the risk of 
childhood acute leukemia. They also measured the association between MTHFR and MTRR 
genetic polymorphisms and acute leukemia.  
Cases and controls were 14 years or younger. The 764 cases were identified from the French 
National registry of Childhood Hematopoietic Malignancies between January 2003 and 
December 2003. These cases were frequency matched with 1681 randomly selected 
controls. 
Folic acid supplementation before and during pregnancy was associated with a substantial 
and significant reduction in the odds ratios of childhood acute leukemia. The association was 
the same in different subtypes of leukemia. The results also suggest that the genotype 
homozygous for variants of the genes required for folate metabolism may be a risk factor for 
acute leukemia. 
2.5.2 Systematic reviews and meta-analyses 
An overview of systematic reviews and meta-analyses included in this report is presented in 
Table 2.5.2-1. 
Table 2.5.2-1 Overview of meta-analyses with folic acid reporting cancer incidence.  








7 of 26 0.4-20 mg/day Cancer, various 
and total cancer 
Total cancer 1.04 (0.97-1.11) 
Qin et al. 
(2013) 
3 of 15 0.5-40 mg/day Cancer, various 
and total cancer 
Total cancer (1.05 (0.99-1.11) 
Vollset et 
al. (2013) 




2 of 6 0.5-1 mg/day Total cancer Total cancer 1.21; 1.05-1.39 
Wien et al. 
(2012) 
5 of 10 0.5-5 mg/day Cancer, various 
and total cancer 
Total cancer 1.07 (1.00-1.14). Six 
RCTs reported prostate cancer 





3 of 3 0.5-1  mg/day Colorectal 
adenomas 
RR was 0.98 (95% CI 0.82,1.17) 
for all adenomas and 1.06 
(0.81,1.39) for advanced lesions 
Fife et al. 
(2011) 
2 of 3 0.5-1  mg/day Colorectal 
adenomas 
After 3 years; OR was 1.09 (0.93-
1.28). Above 3 years; OR was 1.35 
(1.06-1.70) 
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3 of 6 0.5-5  mg/day Colorectal 
adenomas 
OR was 1.08 (0.87-1.33) 
Mackerras et al., 2014 
The meta-analysis "Folic acid, selected cancers, and all-cause mortality" was published in 
2014 (Mackerras et al., 2014). The purpose of this meta-analysis was to conduct a 
systematic review of trials of folic acid supplementation on cancer incidence (total and site 
specific [colorectal, lung, breast, prostate]). In addition, the relation between folic acid and 
recurrence of colorectal adenoma, and total mortality, was examined. The search did not 
place any restrictions on health or disease outcome in the trials, as long as they reported any 
cancer outcome. The investigators included 26 RCTs. The search was conducted in May 
2013. MEDLINE was searched from January 1, 2001 to 16 May 2013. Cochrane CENTRAL 
was also searched on May 16 2013. 
The folic acid dosed in the trials varied from 0.4-20 mg/day. Trials were excluded if folic acid 
was administered in a broad multivitamin/mineral supplement, but studies with multiple B-
vitamins were included. Trials had to administer folic acid and placebos for one year or 
longer and have a follow-up period of at least one year. Any placebos for folic acid had to be 
a blank or minimal dose of folic acid; factorial designs testing other substances were 
permitted. 
Overall relative risks (RR) were calculated using counts from each study. An overall weighted 
(unadjusted) RR for each outcome was calculated de novo from the numbers randomised 
and event numbers using the DerSimonian-Laird inverse variance random effects method. Its 
95% CI was calculated using the Greenland-Robins formula.  
No significant associations between folic acid supplementation and overall or site- specific 
cancer, or all-cause mortality, were found. RR for total incident cancer (13 studies) was 1.04 
(95% CI: 0.97-1.11).  
In conclusion, no significant relation was found between folic acid supplementation, up to 
5 mg per day, and risk of cancer or mortality. 
In this meta-analysis seven studies with single folic acid supplementation reporting cancer 
were included and among these, only three studies had cancer (colorectal) as primary 
outcome (Cole et al., 2007; Logan et al., 2008; Wu et al., 2009). 
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Qin et al., 2013 
In 2013, Qin et al published the meta-analysis "Folic acid supplementation and cancer risk" 
(Qin et al., 2013). The purpose of this meta-analysis was to systematically evaluate the 
effect of folic acid supplementation on cancer risk in RCTs. Post-treatment trials and 
observational follow-up studies were not included. The investigators searched the MEDLINE 
database of studies published from January 1966 to October 2012. 15 trials were included in 
the final analyses. Of the 15 trials, 13 reported total cancer incidence, and fewer reported 
site specific cancers or cancer mortality. Folic acid dose ranged from 0.5–40 mg/day (the 
highest dose in a study on patients with renal disease), with varying inclusion of other B-
vitamins. Duration of the intervention ranged from 24 to 88 months. 
Studies were assessed for quality of randomisation, blinding, reporting of withdrawals, 
generation of random numbers and concealment of allocation (possible score 0-5). Quality of 
the 15 trials ranged from 3-5. 
Relative risk (RR) was used to measure the effect of folic acid supplementation on risk of 
cancer using a random-effects model. Possible effect modifications of several variables were 
examined. 
Overall, folic acid supplementation had no significant effect on total cancer incidence 
(RR=1.05, 95% CI 0.99-1.11), colorectal cancer, other gastrointestinal cancer, prostate 
cancer, other genitourinary cancer, lung cancer, breast cancer, hematological malignancy 
and total cancer mortality. A significantly reduced risk was found for melanoma (RR=0.47; 
95% CI 0.23-0.94). A higher total cancer incidence risk from folic acid supplementation was 
found in trials with the highest proportion of participants on lipid lowering drugs (RR=1.10; 
1.00-1.20) or with lower percent baseline hypertension (RR=1.08; 1.00-1.16). 
The authors concluded that folic acid supplementation had no significant effect on the 
incidence of total cancer or those mentioned above, except for a reduced risk of melanoma. 
In this meta-analysis only three of the included studies were interventions with folic acid 
supplementation only, and with cancer as an endpoint (Cole et al., 2007; Logan et al., 2008; 
Wu et al., 2009). 
Vollset et al., 2013 
The meta-analysis "Effects of folic acid supplementation on overall and site-specific cancer 
incidence during the randomised trials: Meta-analyses of data on 50 000 individuals" was 
also published in 2013 (Vollset et al., 2013). The purpose of this meta-analysis was to 
measure any effects on overall and site-specific cancer rates in randomised trials of folic acid 
supplementation at doses higher than those obtained from fortification. Thirteen randomised 
trials were included, 10 on prevention of cardiovascular disease, three in patients with 
colorectal adenoma. All trials were completed before 2011.  
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Doses in the trials ranged from 0.5-2.5 mg folic acid per day. One trial used 40 mg/day 
(renal disease patients). Treatment duration in each trial was of at least one year, with 
average treatment duration of 5.2 years. 
Unique to this meta-analysis is that the investigators obtained individual-level data from each 
trial, totaling 49 621 participants. Log-rank analyses were used to calculate cancer incidence 
rate ratio (RR). Folic acid supplementation had no significant effect on overall cancer 
incidence during the first five years of treatment in the trials of cardiovascular disease 
prevention (RR=1.06, 95% CI 0.99-1.13). No trend towards greater effect with longer 
treatment was seen. There were no significant effects of folic acid supplementation on the 
incidence of cancer of the large intestine, prostate, lung, breast or any other specific site. In 
the three trials among patients with colorectal adenoma, the meta-analysis found a non-
significant increases risk RR= 1.33 (95% CI 0.98-1.80). 
The authors concluded that folic acid supplementation had no significant effect on cancer 
incidence. 
In this meta-analysis only three of the included studies were interventions with folic acid 
supplementation only, and with cancer as an endpoint (Cole et al., 2007; Logan et al., 2008; 
Wu et al., 2009). 
Baggott et al., 2012 
The "Meta-analysis of cancer risk in folic acid supplementation trials" by Baggott et al. was 
published in 2012 (Baggott et al., 2012). The purpose of this meta-analysis was to evaluate 
the risk of cancer secondary to folic acid supplementation. Six randomised placebo-controlled 
trials of folic acid supplementation were included in the final analysis. A search of PubMed 
was conducted on June 11, 2009. Subsequently, PubMed was searched on a nearly daily 
basis using the key word ‘folate’ to update the search – it is not clear which was the last 
search date. 
Included studies used 0.5 – 2.5 mg folic acid per day. Supplements included other nutrients. 
The duration of intervention was 12 months or more, with an average duration of seven 
years. 
The authors report a weighted analysis of trial-specific effects, expressed as relative risks 
(RR). One of the six trials found a significantly increased risk of cancer, the others found no 
significantly increased risk. Overall, the total cancer incidence were higher in the folic acid-
supplemented groups than in the placebo groups (RR=1.21; 1.05-1.39).  
The authors concluded that total incidence of various cancers were higher in the folic acid-
supplemented groups than in the non-folic acid- supplemented groups. 
The article is very short and does not provide detailed enough information on the various 
studies included (or excluded) in the meta-analysis. 
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In this meta-analysis only two of the included studies were interventions with folic acid 
supplementation only, and with cancer as an endpoint (Cole et al., 2007; Logan et al., 2008). 
Wien et al., 2012 
In 2012, Wien et al. published the systematic review and meta-analysis "Cancer risk with 
folic acid supplements" (Wien et al., 2012). The purpose of this meta-analysis was to explore 
if there is an increased cancer risk associated with folic acid supplements. Nineteen studies, 
including 12 RCTs were included in the overall analysis, 10 of the 12 trials reported overall 
cancer incidence. 
The search was conducted during March-May 2010, using MeSH and free-text search terms 
for folate, folic acid, cancer and neoplasm. The following electronic databases were 
searched: EMBASE, Ovid MEDLINE, Cochrane Library, Centre for Reviews and Dissemination, 
NHS evidence, Clincial evidence, and others.  
Doses of folic acid in the studies were at least 0.4 mg/day, and up to 40 mg/day in one 
study of renal disease patients. Folic acid supplements given were with or without other B-
vitamins. 
The quality of the included studies was assessed using the Cochrane Collaboration’s tool for 
Risk of Bias assessment for RCTs and checklists for cohort and case-control studies. 
When feasible, the authors pooled data by meta-analyses with Cochrane Collaboration 
software and used random-effects model calculating RRs. The PRISMA statement for 
reporting systematic reviews and meta-analyses were used and RRs were reported. 
In the 10 RCTs reporting overall cancer incidence, the RR associated with folic acid 
supplements was 1.07 (1.00-1.14). Six RCTs reported prostate cancer incidence, with a 
combined RR=1.24 (1.03-1.49). No significant increased risk for any other cancer type was 
found. Six trials reporting overall cancer mortality found no significant differences between 
folic acid supplementation versus not (RR=1.09, 95% CI 0.90-1.30). 
The authors concluded that meta-analysis of 10 RCTs showed a borderline significant 
increase in incidence of overall cancer in the folic acid group. Prostate cancer was the only 
site-specific cancer where folic acid significantly increased the risk. 
In this meta-analysis five of the included studies were interventions with folic acid 
supplementation only, and with cancer as the endpoint (Charles et al., 2004; Cole et al., 
2007; Figueiredo et al., 2009; Logan et al., 2008; Wu et al., 2009). 
Figueiredo et al., 2011 
The meta-analysis "Folic acid for the prevention of colorectal adenomas: Combined analysis 
of randomized clinical trials" was published in 2011 (Figueiredo et al., 2011). The aim of this 
meta-analysis was to evaluate the recurrence of colorectal adenomas in patients treated for 
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the disease. Treatment was 0.5 mg or 1 mg per day of folic acid for mean 30.6 months. The 
authors used random-effects meta-analysis to estimate risk ratio (RR). In this meta-analysis 
all participants in the study of Cole et al. and Logan et al. are included, not taking aspirin use 
into consideration. 
No significant increase or decrease in recurrence of adenomas was seen in the folic acid 
group compared to placebo. In the group of participants with low folic acid status 
(<11 nmol/L) at the beginning of the study and in the group of participants with high alcohol 
intake there was a non-significant decrease in adenomas recurrence with folic acid 
supplementation. 
The authors concluded that after 3.5 years of folic acid use there was no clear decrease or 
increase in occurrence of new adenomas in patients with a history of adenoma. 
Fife et al., 2011 
The meta-analysis "Folic acid supplementation and colorectal cancer risk" was also published 
in 2011 (Fife et al., 2011). The purpose of this meta-analysis was to determine the effect of 
folic acid supplementation on colorectal cancer risk. A structured search of the MEDLINE, 
EMBASE, Cochrane and CINAHL databases was undertaken in July 2008. All published full 
text English language articles were searched for that included randomised or pseudo-
randomised comparison of subjects who received folate vs subjects who did not in relation to 
their risk of adenoma or advanced adenomatous lesions, including colorectal cancer. 
Subgroup analysis were used to investigate possible differences in the occurrence of 
adenoma and advanced adenomatous lesions and early (up to three years) vs late more than 
three years) follow-up. 
Three trials met the inclusion criteria and were included in the review. Two studies were 
based either in North America (1021 patients, aged 21-80 years), or in the UK (945 patients, 
aged <75 years), while the third included patients from both North America and Europe 
(5522 patients, aged >55 years). In the third and largest included study, folic acid was given 
in combination with other B-vitamins (B6 and B12). 
Folate supplementation varied between 1 mg /day for three years, follow-up six or eight 
years, 0.5 mg/day for three years, follow-up for three years, and 2.5 mg/day for five years, 
follow-up for five years (+50 mg B6 and 1 mg B12). 
All three trials used computer-generated randomisation and adequate completeness of 
follow-up, blinding and assessments of baseline comparisons between the study groups. 
Weighted treatment effect (using fixed effects) was calculated across trials using RevMan. 
Overall, the risk of adenomatous lesions was not increased among patients who received 
folate supplementation for up to three years. However the risk for adenomatous lesions was 
increased for those receiving folate over three years.  
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In conclusion: this meta-analysis challenges the results from epidemiological studies that 
folate status is inversely related to the risk of developing colorectal cancer. 
In this meta-analysis two of the included studies were interventions with folic acid 
supplementation only, and with cancer as endpoint (Figueiredo et al., 2009; Logan et al., 
2008). 
Ibrahim and Zekri, 2010 
The last included meta-analysis, "Folic acid supplementation for the prevention of recurrence 
of colorectal adenomas" is by Ibrahim and Zekri (2010). The purpose with this meta- 
analysis was to determine the relation between folic acid and the risk of recurrence of 
colorectal adenomas, as conflicting data have emerged from preclinical and clinical studies 
examining this relation. 
A comprehensive search of citations from PubMed, EMBASE, Cochrane databases and 
abstracts of relevant proceedings was made. The aim was to identify interventional 
randomised, placebo-controlled studies where folic acid in specific dose and for specific 
duration was administered to evaluate the effect on recurrence of adenomatous colorectal 
polyps. 
Five eligible trials were identified, with 805 patients in the folic acid groups and 775 patients 
in the placebo group. Data were analysed using RevMan. 
The intake of folic acid varied from 0.5 mg/day for one year in one study, 1 mg /day for one 
year in another study, for two years in a third study and for three years in a fourth study, 
and 5 mg/day for one year in the fifth study. 
Examination of folic acid dose effect showed that the two studies that had used 1 mg/day 
favoured folic acid over placebo with an odds ratio (OR) of 0.62 (95% CI; 0.48-080). 
However, the overall effect for all the included studies was not significant. It was significant 
heterogeneity in methodological quality.  
The present meta-analysis failed to show potential benefit for folate supplementation. 
In this meta-analysis three of the included studies were interventions with folic acid 
supplementation only, and with cancer as the endpoint (Figueiredo et al., 2011; Logan et al., 
2008). 
2.6 Human studies investigating intake of supplementary folic 
acid and concentration of unmetabolised folic acid 
Unmetabolised folic acid (UMFA) has been recovered in the circulation in connection with 
folic acid supplementation and/or fortification, indicating that the conversion of folic acid to 
5-MTHF is not complete. Folic acid is not naturally occurring in the human body and the 
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consequences of UMFA in the circulation are unknown. It has been postulated that UMFA 
could affect the homeostatic regulation of folate and reduce natural-killer cell cytotoxicity 
(Troen et al., 2006). Articles regarding UMFA that were identified during our literature search 
are presented here.   
An overview of studies reporting UMFA that are included in this report is given in Table 2.6-
1. 






Design Intake Main endpoint Results 

















UMFA was detected in 
94.1% of the subjects 
accounting for 1.3% of 
total plasma folate.  
Bailey et al. 
(2010) 
















UMFA in subjects 
fasted for mean 10 
h. 
38% of the older 
population had UMFA but 
this could not be explained 
by intake of folic acid 
alone. Smaller dose 
consumed more frequently 
gave higher UMFA than 
larger dose consumed less 
frequently.  






















UMFA was detected in 
33%. Serum B12 values 
<148pmol/L or MMA>210 
nmol/L UMFA was related 
to lower cognitive test 
scores and lower cell 
volume. The authors 
address the finding that 
low B12 and high folic acid 
intake needs further 
investigations. 
Obeid et al. 
(2010) 
87 pregnant 
women and 29 
cord blood 














Folate and folic acid 
status in serum and 
cord blood.  
Women who used 
supplementation had 
higher folate and 5-MTHF 
and formyl-THF 
concentrations than did 
non supplemented 
women. UMFA did not 
accumulate in cord blood 
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Sweeney et 
al. (2009) 
50 adult blood 
donors (age 27-















Unmetabolised folic acid 
was present in 49 of 50 
blood donors, comprising 
2.25% of total plasma 
folate; and in 18 of 20 
fasted women undergoing 
caesarean section.  
Boilson et al., 2012 
The aim of this cross sectional study by Boilson et al. (2012) was to measure concentration 
of UMFA in plasma in an elderly population. The subjects were fasted and exposed to 
voluntary folic acid fortification and participated in a Lifeways Cross-Generation Cohort study 
in Ireland. One hundred and thirty seven subjects were included, aged 60 to 86 years, mean 
age was 67.4 years, and dietary intake was calculated with use of a Food Frequency 
Questionnaire (FFQ) to evaluate habitual folic acid intake. Two of the included subjects did 
not complete the FFQ. Total plasma folate, red cell folate, plasma UMFA and homocysteine 
concentration were analysed. 
Median folic acid intake through food was 126 µg per day and median folic acid from 
supplements was 200 µg per day but with a huge range. Mean intake of folate from food 
was 351 µg per day among the women and 384 µg among the men. Only eleven subjects 
(8%) had used folic acid supplementation the last 24 hours before blood was drawn, while 
all except 13 (9%) reported use of foods fortified with folic acid. UMFA was detected in 94% 
of the participants accounting for 1.3% of the total plasma folate. UMFA correlated with 
plasma folate, red cell folate and use of folic acid supplementation and intake of folic acid 
fortified foods.  
The authors concluded that UMFA was found in most subjects of this elderly population even 
after an overnight fast, and they argued for careful consideration of legislating mandatory 
folic acid fortification. 
Bailey et al., 2010 
Bailey et al. (2010) conducted a cross sectional study with the aim to examine the 
concentrations of UMFA in relation to intake of folic acid from the diet and from 
supplements. The study is from USA with mandatory folic fortification of bread, flour, corn 
meal, rice, noodles, macaroni, and other grain products since 1998. In this study, surplus 
serum from the National Health and Nutrition Examination Survey (NHANES) 2001-2002 was 
used and 1121 subjects aged over 60 years were included. Dietary data was collected with a 
24-hour dietary recall.  
UMFA was detected in 38% of the subjects and in this group UMFA constituted 6% of the 
serum folate. Folic acid intake through diet was calculated to 178 µg per day and through 
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food supplements to 175 µg per day. UMFA was higher in the group with the highest 
concentration of 5-MTHF. Forty percent of those with UMFA in serum were in the upper 
quartile of total folic acid intake, but total folic acid intake was only moderately correlated to 
UMFA concentration. Serum folate, 5-MTHF and vitamin B12 concentration were higher in the 
group with UMFA, but not in red blood cell folate or homocysteine concentration.  
The authors conclude that the UMFA concentration should be monitored since UMFA might 
be related to cancer development.  
Morris et al., 2010 
Morris et al. (2010) conducted a cross sectional study from USA with the aim to evaluate the 
associations between circulating UMFA or 5-methyl tetra hydrofolate (5-MTHF) and cognitive 
performance. This study included 1858 subjects participating in NHANES from 1999 to 2002 
who had normal renal function and no history of stroke, anemia therapy or disease of the 
liver, thyroid or coronary arteries. The subjects went through a program with blood drawing 
and cognitive and dietary assessments. Cognitive status was tested with a Digit-Symbol 
Substitution test and dietary information was collected with use of 24-h dietary recall 
interview and supplement use was registered for the last 30 days. Blood was drawn after an 
overnight.  
Circulating UMFA was detected in 33% of the subjects and was related to increased odds for 
anemia and alcohol use. In the subjects with low B12 status and who had UMFA in their 
circulation had lower cognitive test scores and lower mean cell volume compared to those 
not having UMFA in their circulation. In those with adequate B12 status a high serum 
concentration of 5-MTHF was related to higher cognitive score. 
The authors conclude that more studies are needed to clarify the hematologic and 
neuropsychiatric risks of low B12 status and high folic acid intake.  
Obeid et al., 2010 
In a cross sectional study from Germany, Obeid et al. (2010) analysed blood drawn at 
delivery from 87 women and also in 24 samples of cord blood from those mothers and in five 
cord bloods not connected with the included women. Peripheral venous blood was obtained 
1-2 hours before delivery. Serum concentrations of UMFA (> 0.29 nmol/L) were found 44% 
of the women and in 55% of the cord blood samples. Pregnant women who had been taking 
400 µg folic acid a day during pregnancy had a non-significant higher concentration of UMFA 
than women not using folic acid supplement. Concentrations of total folates and 5-MTHF and 
formyl-THF were also significantly higher in the former group. The concentration in cord 
blood was not significantly different because of folic acid supplementation. 
The authors concluded that UMFA concentration in cord blood was not higher in 
supplemented than non-supplemented mothers, and that it is not likely that UMFA 
accumulate in the fetus like 5-MTHF and THF.  
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Nguyen et al, 2009 
Nguyen et al. (2009) compared steady state folate concentrations in women of childbearing 
age who were randomised to take 5 or 1.1 mg folic acid daily for 30 weeks. The study was a 
randomised, 2-arm, open-label, intervention study. 40 nonpregnant women between 18-45 
years, who did not take folic acid supplements, were included. The study took place in 
Ontario, Canada. The women were randomised to take either 5 or 1.1 mg folic acid daily for 
30 weeks, as part of a multivitamin pill. The outcome was plasma and red blood cell (RBC) 
folate, measured at baseline and at weeks 2, 4, 6, 12 and 30. During the 30 weeks, one 
woman in each arm dropped out.  
There were no significant differences in plasma or RBC folate at baseline. Plasma folate 
concentrations increased to 165.3 ± 109.9 nmol/L for the 5 mg folic acid group and to 96.8 
± 41.1 nmol/L for the 1.1 mg folic acid group by week 30 (differences were statistically 
significant). Significant differences were also found in RBC folate concentrations between the 
two groups at weeks 4, 6, 12 and 30. Concentrations at week 30 were 2339 ± 782 and 1625 
± 339 nmol/L for the 5 and 1.1 mg folic acid groups, respectively. At baseline, UMFA was 
detected in 70% and 65% of subjects in the 5 and 1.1 mg folic acid groups, respectively. By 
week 30, UMFA was detected in 58% of both groups.  
The authors concluded that the use of 5 mg folic acid per day produced higher blood folate 
concentrations, with a faster rate of folate accumulation, compared with 1.1 mg folic acid. 
Sweeney et al., 2009 
In a small cross sectional study from Ireland, Sweeney et al. (2009) analysed UMFA 
concentration in blood from 50 non-fasting blood donors, among 20 pregnant women and in 
cord blood immediately after caesarean section. The mothers had been fasted at least 8 
hours before the caesarean section. All subjects were interviewed with regard to use of folic 
acid fortified foods and supplements. In 18 (90%) of the mothers and in 17 of the cord 
bloods UMFA was present as well as in 49 (98%) of the blood donors. In the fasted mothers 
UMFA comprised 1.31% of total folate and in the blood donors 2.25% of the total folate was 
UMFA.  
The authors concluded that although low concentrations of UMFA was found it is persistently 
present, also in fasted women which indicate that there would be an constantly exposure to 
UMFA to the fetus and they warn against mandatory fortification of folic acid as long as the 
impact of UMFA in cancer genesis is not known. 
2.6.1 Summary of human studies 
In our literature search (from 2009 to 15 October 2014), we found eight meta-analyses and 
five single studies, where the aims were to study the relation between folic acid 
supplementation and incidence of cancer. Most of the studies investigated adenomas and 
colorectal cancer, but also prostate cancer, breast cancer and total cancer have been 
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evaluated. Brain tumor and childhood leukemia were investigated in two of the included 
single studies. To evaluate the impact of folic acid supplementation, studies conducted with 
multiple B-vitamins were regarded as not relevant setting an UL. Only one of the included 
studies was with healthy subjects. All the other studies (clinical and meta-analyses) were 
performed in patients with adenomas, CVD, gastritis or follow-up of pregnancy interventions. 
Three large clinical studies were performed in patients with diagnosed adenoma with the 
main outcome recurrence of new adenomas. All meta-analyses used two or all three of these 
clinical studies in their analyses. Additionally, a few smaller clinical studies were included in 
some of the meta-analyses.  
Only secondary analysis from one single study (Cole et al., 2007; Figueiredo et al., 2009) 
found a statistically significant increased risk of prostate cancer following folic acid 
supplementation. 
For UMFA in humans we found six studies from countries with liberal voluntary folic acid 
fortification (Ireland) and from countries with mandatory folic acid fortification in addition to 
food supplements. Main results indicate that most subjects exposed to fortification and food 
supplementation with folic acid have circulating UMFA.  
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3 Exposure to folic acid 
In the terms of reference from the Norwegian Food Safety Authority it is stated that is 
important to ensure that the total intake of vitamins and minerals from all sources does not 
exceed the UL. However, folic acid is the synthetic form of the vitamin which is not found 
naturally in foods. VKM is therefore requested to estimate the intake of folic acid from food 
supplements and foods with added folic acid, in all age groups in the population above 1 
year. 
Intakes of folic acid from food supplements have only been calculated for adults 18-70 year 
of age. No information about intakes of folic acid supplements is available for 2-year-olds, as 
the food supplements listed in the questionnaire for the 2-year-olds do not contain folic acid 
(Småbarnskost 2006) (Kristiansen et al., 2009). However, in an article from 2011 among 
seven 2-year-old children the median intake was 20 μg (range 7.5-71.4) of folic acid/day 
from folic acid containing supplements in the supplement users (Hay et al., 2011). 
Data from the national food consumption survey UNGKOST 2000, with food consumption 
data for the age groups 4-, 9-, and 13-year-olds were considered to be too old to be used in 
this opinion. 
Some estimates for intake of folic acid from fortified foods have been conducted in the 
scenarios below.  
Intakes of folate from foods are available for all age groups, but are not relevant for risk 
assessment of folic acid. 
3.1 Description of food consumption surveys 
The estimated intakes of folic acid presented in this opinion are based on data from the 
national food consumption surveys for adults aged 18-70-years (Norkost 3) and information 
for pregnant women who answered the Norwegian Mother and Child Cohort Study (MoBa2) 
food frequency questionnaire in 2008.  
Norkost 3 is based on two 24-hour telephone recall surveys at least one month apart. Food 
amounts were presented in household measures or estimated from photographs (Totland et 
al., 2012). The study was conducted in 2010/2011 and 925 women and 862 men aged 18-70 
years participated (participation rate 37%).  
The Norwegian Mother and Child Cohort Study (MoBa) is a prospective population-based 
pregnancy cohort study conducted by the Norwegian Institute of Public Health (Magnus et 
al., 2006). Participants were recruited from all over Norway from 1999 to 2008. The women 
consented to participation in 40.6% of the pregnancies. The cohort now includes 114 500 
children, 95 200 mothers and 75 200 fathers. 
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3.2 Intake of folic acid from food supplements in adults 
The intakes of folic acid from food supplements are presented in Table 3.1.2-1. Intakes for 
men and women are presented separately, as women are advised to take folic acid 
supplement before and during the first trimester of pregnancy. Only 18% of the men and 
26% of the women in Norkost 3 reported to take folic acid supplements, and the presented 
figures are for those who have reported to use folic acid supplements. Mean intakes of folic 
acid from supplements in those who actually took supplements are 149 µg/day in women 
and 172 µg/day in men. 
Table 3.1.2-1 Intakes of folic acid from food supplements in users only, men (n=152) and women 
(n=240) mean, median and 95-percentile intakes. 
 Mean (SD), µg/day Median, µg/day 95th perc, µg/day 
Men, users only  172 (228) 100 500 
Women, users only 149 (121) 100 400 
3.2.1 Intake of folic acid in pregnant women 
Before and during the three first month of pregnancy women are recommended to take 400 
µg of folic acid as supplements. In 2008, 62% of the women participating in MoBa reported 
use of folic acid supplements with a mean intake of 388 µg/day and 800 µg/day in the 95th 
percentile. Use of several folic acids containing food supplements and use of food 
supplements bought through internet or abroad accounts for the high intake in the 95th 
percentile among the pregnant women (Haugen et al., 2008). 
Table 3.1.2.1-1 Intakes of folic acid from food supplements in pregnant women; all participants and 
users only, mean, median and 95-percentile intakes. 
 Mean (SD), µg/day Median, µg/day 95th perc, µg/day 
All participants 
(n=11 633) 
240 (292) 171 735 
Users only (n= 
7227) 
388 (284) 400 800 
3.3 Scenarios 
VKM is requested to estimate the intake of folic acid from both food supplements and foods 
with added folic acid, in all age groups in the population above 1 year. Intakes of folic acid 
from fortified foods are not available in the national food consumption surveys for any age 
groups. However, folic acid fortified products available on the Norwegian market indicates 
that the present intake of folic acid from fortified foods in the general Norwegian population 
can be expected to be low as most of the fortified products on the Norwegian marked not 
are expected to be consumed on a daily basis. Furthermore, the Norwegian fortification 
model (VKM, 2013) will ensure that consumption of folic acid from fortified foods will not 
exceed UL in any age groups. 
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According to a model for fortification from 2006 and later updates (last in 2013), 53 µg folic 
acid per 100 kcal can be added to foods and drinks without exceeding the UL for folic acid in 
any age group http://vkm.no/dav/88ac29e491.pdf.  
In the following scenarios, 50% of all wheat flour has been fortified with 53 µg folic acid per 
100 kcal. Intakes of folic acid from presumably fortified wheat flour have been calculated 
separately for men and women, and in different age groups with use of consumption data 
from Norkost 3. The results are presented in Tables 3.1.3-1 and 3.1.3-2. Young men would 
be the most exposed group if 50% of wheat flour were fortified, whereas the exposure in 
women in child-bearing age would be somewhat lower. However, none of the adult 
population groups would exceed the present UL of 1 mg/day if the maximum addition 
according to the fortification model is implemented.  
Table 3.1.3-1 Scenario: Intake of folic acid for men (aged 18-70) in µg/day if 50% of all wheat 
flour1 were added 53 µg folic acid per 100 kcal. 
 N Mean Median 95th percentile 
Men, all 862 148 136 289 
Men <30 years 138 182 169 379 
Men >30 years 724 141 131 274 
Men <45 years 453 163 148 310 
Men >45 years 409 132 124 247 
1Scenario addition of 53 µg folic acid per 100 kcalr wheat flour in accordance with the updated model 
for fortification: http://vkm.no/dav/88ac29e491.pdf. 
Table 3.1.3-2 Scenario: Intake of folic acid for women (aged 18-70) in µg/day if 50% of wheat flour1 
were added 53 µg folic acid per 100 kcal. 
 N Mean Median 95th percentile 
Women, all 925 98 90 195 
Women <30 years 143 107 101 210 
Women >30 years 782 96 87 195 
Women <45 years 568 103 97 204 
Women >45 years 357 89 80 177 
1Scenario addition of 53 µg folic acid per 100 kcal wheat flour in accordance with the updated model 
for fortification: http://vkm.no/dav/88ac29e491.pdf. 
VKM is also requested to elucidate the consequence of amending the maximum limit for folic 
acid in food supplements for the total intake of folic acid (from food supplements and foods 
added folic acid). VKM has been requested to make calculations for how amendment of the 
maximum limit in food supplement (200, 400 or 600 µg/day) will affect the maximum 
amount of nutrients that can be added per 100 kcal of foodstuff according to the Norwegian 
fortification model (VKM, 2013). The results are presented in Table 3.1.3-2. In adults, an 
increase in maximum limits to 400 or 600 µg folic acid from food supplements will not affect 
the previous conclusions in the fortification model. However, an increase in maximum limits 
will imply a reduction in fortification for other age groups or an exceedance of UL. The 2-
year olds are the most vulnerable age groups with the lowest UL for folic acid. The empty 
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fields in the table, indicate that the change in maximum limit will result in intakes of folic acid 
from supplements and fortified food/drinks at or above UL in these age groups. 
Table 3.1.3-2 Scenarios with amended maximum content of folic acid in food supplements - 
calculations made in the Norwegian fortification model (VKM, 2013), µg folic acid/100 kcal food or 
drink. 
 200 µg food 
supplement 
400 µg food 
supplement 
600 µg food 
supplement 
2-year olds - - - 
4-year olds 34 µg/100 kcal - - 
9-year olds 48 µg/100 kcal - - 
13-year olds 53 µg/100 kcal* 39 µg/100 kcal - 
Men, 18-70 years 53 µg/100 kcal* 53 µg/100 kcal* 53 µg/100 kcal* 
Women, 18-70 years 53 µg/100 kcal* 53 µg/100 kcal* 53 µg/100 kcal* 
*The 2-year olds are the most vulnerable age group due to the lowest UL. 
3.4 Summary exposure 
Eighteen per cent of men and 26% of women in Norkost 3 reported to take folic acid food 
supplements. Mean intake of folic acid from supplements in those who actually take 
supplements are 149 µg/day in women and 172 µg/day in men. Information on intake of 
folic acid supplements for other age groups is not available. 
Among women participating in MoBa in 2008, 62% reported use of folic acid. Mean intake 
was 388 µg/day and 800 µg/day in the 95th percentile. Use of several folic acids containing 
food supplements and use of food supplements bought through internet or abroad accounts 
for the high intake in the 95th percentile among the pregnant women. 
Intakes of folic acid from fortified foods are not available in the national food consumption 
surveys for any age groups. However, according to a model for fortification from 2006 and 
updates (last in 2013), 53 µg folic acid per 100 kcal can be added to foods and drinks 
without leading to exceedance of UL for folic acid in any age groups.  
In scenarios where 50% of wheat-flour presumably have been fortified with 53 µg folic acid 
per 100 kcal, young men would have the highest intakes, whereas the exposure in women at 
child bearing ages, would be somewhat lower.  
If maximum limits in food supplements are increased, this will imply a reduction in 
fortification for the younger age groups or an exceedance of UL 
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4 Risk characterisation 
In 2000, SCF concluded that the best available estimate for a lowest-observed-adverse-effect 
level (LOAEL) for folic acid was 5 mg, and that dosages up to 1 mg of folic acid were unlikely 
to cause masking of hematological signs in patients with pernicious anemia, and the UL for 
folic acid was set at 1 mg. 
The totality of evidence from randomised control trials up to the date of the ESCO report 
(2009) did not conclude that folic acid increased cancer risk. However, based on results from 
the reviewed studies, increased cancer risk from folic acid supplementation could not be 
excluded. The report (from 2009) stressed that interpretation of results from available 
studies were limited due to the short duration of the trials and power of the meta-analysis. 
The ESCO report (2009) concluded that intake of folic acid should not exceed the established 
UL of 1 mg/day (SCF, 2000). The UL was based on limited data, and ESCO underlined that if 
further data become available, this UL needs to be discussed further.  
It was also stated that the relationship between folic acid and cancer requires to be clarified 
by studies designed with sufficiently long follow-up periods addressing the biological 
hypothesis for the dual effect of folic acid on cancer development (EFSA, 2009). 
In light of this, the results relevant for setting an UL from published studies from 2009 up to 
15th of October 2014 are discussed below. 
4.1 Folic acid and cancer 
Five single studies and eight meta-analyses are included for evaluation of the relation 
between folic acid supplementation and incidence of cancer. The majority of the studies are 
related to adenomas and colorectal cancer, but also prostate cancer, breast cancer and total 
cancer have been evaluated as secondary outcomes. Brain tumor development in children 
born to mothers using folic acid supplementation during pregnancy was investigated in one 
study, and another studied childhood acute leukemia following perinatal folic acid 
supplementation among the mothers. 
Since 2009, one RCT of 791 healthy subjects older than 50 years has been published (Gao et 
al., 2013). The outcome was development of colorectal adenomas, and an unadjusted 
reduced risk of advanced colorectal adenomas after three years was found in the group 
randomised to receive 1 mg folic acid compared with a control group receiving a multivitamin 
tablet not containing folic acid. In this study the treatment group was not blinded and the 
follow-up procedures in the two groups differed. The study was not designed to look at 
adverse effects and does not add information useful with regard to establishing an UL for 
folic acid. Conclusion: An intake of 1 mg folic acid per day for 3 years seems safe for healthy 
subjects older than 50 years.  
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A nested case-control study investigated the recurrence of colorectal adenoma among 338 
participants who received 1 mg of folic acid and 334 patients who received placebo for 3 to 
6.5 years (Wu et al., 2009). No significant association was found in participants with an 
adequate folate status, but reduced risk of adenomas was observed in subjects with 
inadequate folate status. Conclusion: One milligram folic acid supplementation seems safe 
for subjects treated for colorectal adenomas.  
Figueiredo et al. (2009) analysed occurrence of prostate cancer among men (n=643) with 
colorectal adenomas treated with 1 mg folic acid for a median of 7 years. An age-adjusted 
hazard ratio for prostate cancer was 2.63 (1.23, 5.65) for the men randomised to treatment 
compared with placebo. This is a secondary finding of the Cole et al. (2007) study originally 
looking at recurrence of colorectal adenomas and cancer. The study was poorly powered 
(few prostate cancer cases). Conclusion: Further clinical studies with prostate cancers as 
primary outcome are needed to confirm these findings.  
Two case-control studies have examined the development of cancer in offspring of mothers 
using folic acid during the perinatal period; one studied leukemia (Amigou et al., 2012) and 
the other brain cancer (Milne et al., 2012). The dosage of folic acid was reported, but the 
use of other multivitamins was not detailed. Conclusion: These two studies reported on a 
protective effect of folic acid supplementation and therefore not useful for evaluating an UL.  
Only one meta-analysis published after 2009 included studies with single folic acid arms 
(Figueiredo et al., 2011). This meta-analysis included the three studies by Cole et al. (2007), 
Logan et al. (2008) and Wu et al. (2009), and concluded that there was no clear decrease or 
increase in recurrence of new adenomas in patients after 3.5 years with the use of 0.5 to 1 
mg folic acid per day. Conclusion: Folic acid supplementation of 0.5 to 1 mg seems safe in 
adenoma treated subjects with respect to new adenoma development. 
Conclusion: None of the studies regarding cancer published after 2009 provide significant 
support to alter the existing UL for folic acid supplementation. 
4.2 Unmetabolised folic acid 
Concerns have been raised regarding potential adverse effects associated with the presence 
of unmetabolised folic acid (UMFA) in the circulation. Six of the studies identified during the 
literature search report on UMFA in subjects taking supplements or consuming fortified 
foods. In the study by Sweeney et al. (2009), 2.25% of the total plasma folate was UMFA, 
compared to 1.3% in the study of Boilson et al. (2012). Both fasting and non-fasting 
subjects were included in these studies. A study from Germany among pregnant women 
reported that women who took 400 µg of folic acid supplements had higher concentrations 
of UMFA in the blood compared to women not using folic acid supplements, but no 
differences were found in umbilical cord blood (Obeid et al., 2010). Two studies from USA, 
both analysing data from NHANES 1999 to 2003, found that among persons older than 60 
years almost 40% of the participants had UMFA in the circulation (Bailey et al., 2010; Morris 
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et al., 2010). USA implemented mandatory folic acid fortification of grain products in 1998 
and hence more or less all subjects in these studies had intakes of folic acid. It was reported 
that those who used folic acid supplements had significantly higher concentrations of UMFA 
in the circulation than those who did not (Bailey et al., 2010), but that UMFA was only 
moderately correlated with folic acid intake. In the study of Morris et al. (2010), the authors 
also looked at the relation between UMFA and anemia, macrocytosis and cognitive 
performance. They found that in subjects with low vitamin B12 status, the presence of UMFA 
was related to lower cognitive test scores and lower mean cell volume. In the group with low 
vitamin B12 status, a high serum folate concentration was associated with increased odds of 
anemia and decreased odds for macrocytosis.  
Conclusion: UMFA is found in subjects who use folic acid supplements or who are subjected 
to folic acid food fortification. The impact of UMFA in the circulation and the extent to which 
UMFA contributes to the development of cancer or other undesirable health effects is still of 
concern. The reviewed studies do not contribute with evidence useful in terms of a potential 
modification of the current UL for folic acid. 
4.3 Evaluation of ULs for folic acid 
It has previously been established that folic acid has the ability to reverse megaloblastic 
anemia due to vitamin B12 deficiency and thus delay appropriate treatment with B12. 
Longstanding B12 deficiency can have serious irreversible neurological consequences. A 
Tolerable Upper Intake Level (UL) for folic acid was set in 2000 by The Scientific Committee 
on Food (SCF) and was based on studies among vitamin B12 deficient patients who were 
treated with doses of folic acid up to 30 mg per day. Doses >5mg per day were reported to 
give neurological relapses in these patients and the LOAEL of 5 mg folic acid per day was 
set. An uncertainty factor of 5 was applied and UL for folic acid was calculated to 1 mg per 
day (SCF, 2000).  
The latest main concerns of folic acid supplementation and adverse effects have been related 
to cancer development(Ebbing et al., 2009; EFSA, 2009; EFSA, 2010). While adequate folate 
status seems to be protective for cancer development, it has been suggested that folic acid 
supplementation might enhance cancer progression. In our literature search meta-analyses 
and clinical studies were related to colorectal adenoma patients and it seems that intake of 
up to 1 mg of folic acid for 3 years was neither protective nor increased the rate of new 
adenomas. No further studies were found to clarify the relationship between folic acid intake 
and cancer designed with sufficiently long follow-up periods (EFSA, 2009). 
Conclusion: At this time there are no new arguments for increasing or decreasing the UL for 
folic acid in relation to cancer. In elderly low cognitive function among those with low 
vitamin B12 status were associated with UMFA in the circulation (Morris et al., 2010). If future 
studies confirm the finding it might call for a reevaluation of UL for folic acid. 
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4.3.1 General population, different age groups 
Vitamin B12 deficient: In individuals with poor or suboptimal vitamin B12 status, folic acid 
intake may mask otherwise easily recognisable consequences of vitamin B12 deficiency and 
accordingly delay treatment with vitamin B12. There are also indications that supplementation 
with folic acid may accelerate cognitive decline in elderly and that this effect is aggravated in 
B12 deficiency. 
The prevalence of vitamin B12 deficiency in most populations is not known but there are 
indications that as many as 4% of elderly are deficient even in affluent countries. This 
number is probably higher in poor countries. Many young children (<5 years) also have poor 
vitamin B12 status (Allen, 2004; TaneJa et al., 2007). The extent to which folic acid has 
negative health consequences in these is not known. However, in a recent RCT in a 
population of young children with poor vitamin B12 status in North India, supplementation 
with 2 RDA of folic acid for six months doubled the risk of persistent diarrhea (Taneja et al., 
2013). Concomitant vitamin B12 supplementation did not modify this effect. However, the 
doses of vitamin B12 given may have been too low to sufficiently replenish their vitamin B12 
stores. 
4.3.2 Special groups 
The most important source of vitamin B12 is animal source foods such as meat, egg and milk. 
Vegetarians and vegans are accordingly at risk for deficiency and at a higher risk of adverse 
effects from high doses of folic acid.  
Dihydrofolate reductase (DHFR) activity: Folic acid has to be reduced by the enzyme 
DHFR before it can enter normal metabolism. Many have a mutation in the DHFR gene which 
leads to higher levels of UMFA in the circulation (Kalmbach et al., 2008). 
Antifolate therapy usually target human and microbial DHFR activity. Intake of folic acid may 
interfere with these drugs and result in high levels of UMFA in the circulation. There is also a 
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5 Uncertainties 
5.1 Uncertainties linked to study design  
Evidence considered in this report on risk of cancer development following folic acid 
supplementation is collected from three RCTs among patients with adenomas (Cole et al., 
2007; Logan et al., 2008; Wu et al., 2009). One meta-analysis of the three RCTs was also 
used. RCTs rank as number one among primary studies on the quality-of-evidence scale, 
surpassed only by meta-analyses of RCTs regarding evidence quality.  
Compliance with the study protocol was controlled through questionnaires by mail every 4 
months in the study of Cole et al. (2007). In the study of Logan et al. (2008) all participants 
were interviewed by phone every 4 months by a nurse to check for compliance. Tablet count 
was performed once a year. In the study of Wu et al. (2009), participants were asked for a 
blood sample to assess adherence with the study protocol. Compliance with the study 
protocol was evaluated as acceptable in all three studies. However, low compliance in these 
studies could lead to an underestimation of a negative effect. The generalisability of results 
from the three studies to the general public or to cancers other than colorectal cancer is 
limited, since all three studies were performed in patients with colorectal adenomas. 
However, since no increased risk of colorectal cancers was found in this patient group, which 
is known to be more disposed for colorectal cancer, it seems unlikely that healthy subjects 
would be at a higher risk. 
Ethnicity may theoretically play a role both with regard to health effect outcomes and doses 
tolerated. Most studies referred to are performed in Caucasian dominated populations but 
whether the effects differed by ethnicity was not addressed.  
Most trials combine folic acid with other vitamins, and only the three trials mentioned above 
included an intervention arm of folic acid alone. However, the dosage used in these studies 
is at or below the current UL for folic acid. This UL was set because of adverse effects of folic 
acid supplementation in subjects with low B12 status. In the study by Cole et al. (2007), B12 
status was checked before inclusion and patients were not included if B12 status was poor. 
Adverse effects were reported in all three studies with no significant differences between 
folic acid and placebo treated patients.  
With regard to UMFA, no toxicological data exist.  
5.2 Dietary assessment and concentration of folic acid in foods 
and supplements 
Folic acid is a synthetic stable chemical form of folate which is not found naturally in food. 
Folic acid is the most common form of folate used in food fortification and in food 
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supplements. Most European countries, as well as Norway, have not implemented mandatory 
fortification of folic acid, and so far Norway has very few products voluntarily fortified with 
folic acid on the market which would contribute to intake of folic acid in the general 
population. When evaluating folic acid intake, the information given in the labelling of food 
supplements should therefore give a good estimation of actual intake of this vitamin. 
Bioavailability of folic acid is about 85%. Possible source of error is the content of folic acid 
in the food supplements. Validation studies with folic acid have shown a significant increase 
in blood folate with folic acid supplementation, but folate comes also from the diet which 
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6 Conclusions with answers to the 
terms of reference 
The Norwegian Food Safety Authority requests the Norwegian Scientific Committee for Food 
Safety (VKM) to assess the risk of folic acid in food supplements. The risk assessment should 
address the following aspects and questions: 
In 2000, the Scientific Committee on Food (SCF) set a tolerable upper intake level (UL) for 
folic acid of 1 mg/day for adults. ULs for adolescents and children were adjusted downwards 
on the basis of body weight. Subsequently, new scientific evidence has emerged suggesting 
a possible link between high intake levels of folic acid and risk of cancer. In the light of the 
latest scientific data on folic acid, should the UL be amended?  
VKM concludes that no new scientific data have been published on the issue of folic 
acid supplementation and cancer risk that would support amending current UL. Doses 
up to UL for folic acid have been investigated in patients with colorectal adenomas 
but no significant increase or decrease in colorectal cancer risk was reported.  
Unmetabolised folic acid was found in subjects who use folic acid supplements or who 
are subjected to folic acid food fortification. The impact of unmetabolised folic acid in 
the circulation and the extent to which this contributes to the development of cancer 
or other undesirable health effects is still of concern. The reviewed studies do not 
contribute with evidence useful in terms of a potential modification of the current UL 
for folic acid based on cancer risk. 
It is important to ensure that the total intake of vitamins and minerals from all sources does 
not exceed the UL. However, folic acid is the synthetic form of the vitamin which is not found 
naturally in foods. VKM is therefore requested to estimate the intake of folic acid from food 
supplements and foods that are added folic acid, in all age groups in the population above 
1 year. 
No information about intake of folic acid supplements is available for 2-year-olds, 
because food supplements containing folic acid was not asked for in the survey of 
2012. Data from the national food consumption survey UNGKOST 2000, with food 
consumption data for the age groups 4-, 9-, and 13-year-olds were considered to be 
too old to be used in this opinion. 
The maximum dose of folic acid allowed in food supplements in Norway is 200 µg, 
and mean folic acid intake from food supplements among adults in Norway assessed 
in Norkost 3 was 172 µg per day for men and 149 µg per day for women (among 
users). The 95% percentile was 500 µg for men and 400 µg for women. Supplements 
for pregnant women contain 400 µg folic acid and the mean intake of folic acid was 
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388 µg per day and 800 µg per day in the 95th percentile in this group according to 
MoBa.  
Information about folic acid intake from fortified foods in Norway cannot be 
calculated because folate and folic acid are not distinguished in the Norwegian food 
tables. However, folic acid fortification is regulated through the Norwegian food 
fortification model ensuring a safe intake provided food supplement intake is 200 µg 
per day or below. This was illustrated in the scenario where 50% of all wheat flour 
was fortified with 53 µg folic acid per 100 kcal. The estimated intake in the 95th 
percentile was 379 µg per day for men and 210 µg per day for women.  
VKM is requested to elucidate the consequence of amending the current maximum limit of 
200 µg for folic acid in food supplements for the total intake of folic acid (from food 
supplements and foods added folic acid). 
Increasing the maximum limits in food supplements to 400 µg will imply exceedance 
of UL for children younger than 6 years and an intake close to UL in children 7-10 
years. An increase in the maximum limits in food supplements to 600 µg will imply 
exceedance of UL for children younger than 10 years and an intake close to UL in 
children 11-14 years. Increasing the maximum limits in food supplements to 400 µg 
or 600 µg will not imply exceedance of UL among adults as evaluated in the current 
food fortification model. 
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7 Data gaps 
In reviewing the literature, three major issues limiting the possibilities to draw firm 
conclusions regarding a possible harmful effect of folic acid supplementation appear: 
• Most randomised controlled clinical trials of folic acid supplementation have used 
other vitamins in addition to folic acid. Thus, it is not possible to distinguish a 
possible adverse effect of folic acid from that of the other vitamins.  
• Most studies have been of relatively short duration, cancer is a condition which 
usually develops over several years. 
• Few studies of folic acid supplementation have had cancer as the primary endpoint.  
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Appendix I, Search strategy 
Database: Embase <1974 to 2014 September 03> 
Search Strategy: 
1 cancer*.mp. (2229418) 
2 folic acid supplement*.mp. (2351) 
3 1 and 2 (206) 
4 limit 3 to (human and (danish or english or norwegian or swedish) and yr="2009 -
Current") (88) 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) 
Daily, Ovid MEDLINE(R) and Ovid OLDMEDLINE(R) <1946 to Present> 
Search Strategy: 
1 folic acid supplement*.mp. (1870) 
2 cancer*.mp. or Neoplasms/ (1306631) 
3 1 and 2 (139) 
4 limit 3 to (humans and yr="2009 -Current" and (danish or english or norwegian or 
swedish)) (44) 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) 
Daily, Ovid MEDLINE(R) and Ovid OLDMEDLINE(R) <1946 to Present> 
Search Strategy: 
1 "folic acid*".m_titl. (6853) 
2 limit 1 to (humans and yr="2009 -Current" and (danish or english or norwegian or 
swedish) and randomized controlled trial) (100) 
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Appendix II; Excluded papers 
Reference Topic Reason for exclusion 
Burdge G.C., Lillycrop K.A. (2012) Folic acid supplementation in pregnancy: Are 
there devils in the detail? British Journal of Nutrition 108:1924-1. 
Folic acid in pregnancy. A discussion article. No original data. 
Clarke R. et al. (2010) Effects of lowering homocysteine levels with B vitamins on 
cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 
randomized trials involving 37 485 individuals. Archives of Internal Medicine 
170:1622-16. 
Folic acid supplementation 
for 5 years and Hcy. 
Main outcome CVD. Only multiple vitamin 
supplementations. 
Gargari B.P. et al. (2011) Effect of folic acid supplementation on biochemical 
indices in overweight and obese men with type 2 diabetes. Diabetes Research 
and Clinical Practice 94:33-38. 
Effect of folic acid 
supplementation in 
overweight and obese with 
type 2 diabetes. 
No information about cancer risk. 
Hubner R.A., Houlston R.S. (2009) Folate and colorectal cancer prevention. British 
Journal of Cancer 100:233-239. 
Colorectal cancer 
prevention. 
A discussion article. Not a systematic review 
or meta-analyses. 
Kotsopoulos J. et al. (2012) Folate and breast cancer: What about high-risk 
women? Cancer Causes and Control 23:1405-1420. 
Folate and women with 
high risk for breast cancer. 
Discussion paper. 
Levine A.J. et al. (2010) Baseline plasma total homocysteine and adenoma 
recurrence: Results from a double blind randomized clinical trial of aspirin and 
folate supplementation. Cancer Epidemiology Biomarkers and Prevention 
19:2541-2548. 
Aspirin and folate 
supplementation and 
plasma homocysteine and 
adenoma recurrence. 
Concludes on plasma tHcy, not folic acid, and 
risk of colorectal adenomas. 
Levine A.J. et al. (2010) A candidate gene study of folate-associated one carbon 
metabolism genes and colorectal cancer risk. Cancer Epidemiology Biomarkers 
and Prevention 19:1812-1821. 
 Discussion if geneotype had anything to say 
about folic acid supplementation on colorectal 
cancer. 
Levine A.J. et al. (2008) MTHFR genotype and colorectal adenoma recurrence: 
Data from a double-blind placebo-controlled clinical trial. Cancer Epidemiology 
Biomarkers & Prevention 17:2409-2415. 
Genotype of MTHFAR and 
colorectal cancer. 
Discussion if geneotype had anything to say 
about folic acid supplementation on colorectal 
cancer. 
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Reference Topic Reason for exclusion 
Lubecka-Pietruszewska K. et al. (2013) Folic acid enforces DNA methylation-
mediated transcriptional silencing of PTEN, APC and RARbeta2 tumour suppressor 
genes in breast cancer. Biochemical and Biophysical Research Communications 
430:623-628. 
Folic acid and regulation of 
tumor suppressor genes. 
In vitro study. 
Lucock M., Yates Z. (2009) Folic acid fortification: A double-edged sword. Current 
Opinion in Clinical Nutrition and Metabolic Care 12:555-564. 
Folic acid fortification. A discussion article. 
Manizheh S.M. et al. (2009) Comparison study on the effect of prenatal 
administration of high dose and low folic acid. Saudi Medical Journal 30:88-97 
Folic acid supplementation 
in pregnancy 5 mg/day and 
0.5 mg/day. 
Cancer is not a topic in this article. 
Nan H., Lee J.E., Rimm E.B., Fuchs C.S., Giovannucci E.L., Cho E. (2013) 
Prospective study of alcohol consumption and the risk of colorectal cancer before 
and after folic acid fortification in the United States. Annals of Epidemiology 
23:558-563 
Alcohol consumption, 
colorectal cancer and folic 
acid. 
Prevention report - low dose of folic acid. 
Ortega-Garcia J.A. et al. (2010) Case control study of periconceptional folic acid 
intake and nervous system tumors in children. Child's Nervous System 26:1727-
1733 
Periconseptive intake of 
folic acid and 
neuroectoderm tumors in 
children. 
Prevention study. 
Smith D.E.C. et al. (2013) Folic acid supplementation does not reduce intracellular 
homocysteine, and may disturb intracellular one-carbon metabolism. Clinical 
Chemistry and Laboratory Medicine 51:1643-1650 
Folic acid supplementation 
and intracellular Hcy 
concentration. 
Cancer is not a topic in this article. 
Taneja S. et al. (2013) Folic acid and vitamin B-12 supplementation and common 
infections in 6-30-mo-old children in India: A randomized placebo-controlled trial. 
American Journal of Clinical Nutrition 98:731-737 
Folic acid and vitamin B12 
supplementation and 
common infections in 
children performed in India. 
Cancer is not a topic in this article. 
Vila-Nova C. et al. (2013) Periconceptional use of folic acid and risk of miscarriage 
- findings of the Oral Cleft Prevention Program in Brazil. Journal of Perinatal 
Medicine 41:461-466 
Periconceptual folic acid 
supplementation and risk of 
miscarriages. 
Cancer is not a topic in this article. 
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Reference Topic Reason for exclusion 
Weggemans R.M. et al. (2009) Toward an optimal use of folic acid: An advisory 
report of the Health Council of the Netherlands. European Journal of Clinical 
Nutrition 63:1034-1036 
Optimal use of folic acid. An advisory report of the Health Council of 
the Netherlands. No original data. 
Zappacosta B. et al. (2009) Genotype prevalence and allele frequencies of 5,10- 
methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms 
in Italian newborns. Laboratory Medicine 40:732-736 
Folic acid supplementation 
and genotype prevalence. 
Cancer is not a topic in this article. 
Zhou Y.H. et al. (2011) Effect of folic acid supplementation on cardiovascular 
outcomes: A systematic review and meta-analysis. PLoS ONE 6 
Folic acid and 
cardiovascular outcomes. 
Cancer is not a topic in this article. 
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Appendix III; Summary Tables 
RCTs and prospective studies 
Reference Gao Q.Y., Chen H.M., Chen Y.X., Wang Y.C., Wang Z.H., Tang J.T., Ge Z.Z., Chen X.Y., Sheng J.Q., Fang D.C., Yu C.G., 
Zheng P., Fang J.Y. (2013) Folic acid prevents the initial occurrence of sporadic colorectal adenoma in Chinese older 
than 50 years of age: A randomized clinical trial. Cancer Prevention Research 6:744-752. 
Study design and type Prospective, randomised, controlled design comparing daily supplementation with 1 mg folic acid with controls. 
Objective Primary outcome parameter was incidence of any type of CRA (tubulovillous, tubular villous or serrated lesions at 3 year 
follow-up colonoscopy in both groups. Evaluation of plasma folate at the beginning and end of follow-up period. 
Number of participants, country 
and age 
980 individuals from China age more than 50 years. 
Baseline characteristics of study 
subjects/cells 
No adenoma confirmed by colonoscopy entered run–in-period. 120 individuals excluded (unable to avoid taken 
medication or supplements prohibited by the study, decline to continue the study, no adherent, excluded for other 
reasons. No differences in the baseline characteristics between the folic acid and control group. 
Exposure, substance, food, (type 
and amount) 
1 mg/day folic acid supplement, controls treated without folic acid. 
Measurement of exposure 
(biomarker, internal validation) 
Adenomas. 
Follow-up period, drop-outs Seven hundred ninety-one (91.98%) underwent colonoscopy after 3 years of follow-up. The remaining 69 participants 
was lost to follow-up, discontinued the intervention or were unable to avoid regularly taking folic acid for more than 2 
weeks and 2 in each group developed CRCs. 
Health outcome See over. 
Measurement of outcome See over. 
Statistical analysis Enough participants were selected to provide power of at least 80% to detect a risk detection with folic acid using two-
sided statistical significance level of p≤0.05. Data collection was conducted using Case Report Form stored in a 
validated database that conformed GCP requirements. Predefined primary statistical analysis X² test with a significant 
level of 5% comparing the risk of CRA between the two groups. Cox regression methods. 
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Reference Gao Q.Y., Chen H.M., Chen Y.X., Wang Y.C., Wang Z.H., Tang J.T., Ge Z.Z., Chen X.Y., Sheng J.Q., Fang D.C., Yu C.G., 
Zheng P., Fang J.Y. (2013) Folic acid prevents the initial occurrence of sporadic colorectal adenoma in Chinese older 
than 50 years of age: A randomized clinical trial. Cancer Prevention Research 6:744-752. 
Results After 3 years of follow-up, it was found that folic acid supplementation may decrease the risk of CRA. In the intention –
to-treat population, CRA occurred in 64 (14.88%) participants in the folic acid group and in 132 (30.70%) in the control 
group. 3 or more adenomas occurred in 14 participants in the folic group and 20 in the control group. Adenoma 
occurred on the left side of the colon in 42 participants in the folic acid group and 78 in the control group. There was no 
such trend in the right –sided adenoma. Adjustment for age, sex, clinical centre and duration of follow –up at baseline 
did not substantially affect the results. Baseline folic acid levels did not differ between the two groups, but did show a 
difference between the participants who developed CRA and those who did not. The results indicate that there may be 
an effective therapeutic level of folic acid and that people who do not achieve this level may still be at risk of CRA. 
Conclusion Participants with low plasma folate may have a high risk of CRA. Primary prevention with 1 mg /day folic acid 
supplementation could reduce the incidence of CRA, especially left-sided and advanced disease with no previous 
adenomas. 
Confounders adjusted for Age, sex, clinical centre and duration of follow up. 
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Reference Wu K., Platz E.A., Willett W.C., Fuchs C.S., Selhub J., Rosner B.A., Hunter D.J., Giovannucci E. (2009) A randomized 
trial on folic acid supplementation and risk of recurrent colorectal adenoma. American Journal of Clinical Nutrition 
90:1623-1631. 
Study design and type RCT. 
Objective To assess the effect of folic acid supplementation (1mg/day) for 5-6.5 years on recurrence of colorectal adenomas. 
Number of participants, country 
and age 
338 in treatment group and 334 in placebo group collected from Health Professionals Follow-up Study and Nurses’ 
Health Study. Age between 50- 78 years. USA. 
Baseline characteristics of study 
subjects/cells 
Patients were diagnosed with colorectal adenomas which were removed. Folate status before inclusion was a evaluated. 
Exposure, substance, food, (type 
and amount) 
1 mg folic acid supplementation for 5-6.5 years and placebo. 
Measurement of exposure 
(biomarker, internal validation) 
Plasma folate concentration. 
Follow-up period, drop-outs 5-6.5 years. 
Health outcome Recurrence of colorectal adenomas. 
Measurement of outcome Endoscopies.   
Statistical analysis Intention to treat approach. Risk was evaluated by risk ratios calculated with use of generalised linear model. 
Adjustments were made for age, sex, extension group, and time between the start and the last follow up endoscopy. 
Results Incidence of at least one recurrent adenomas was 0.82 (0.59,1.13). Among patients with low plasma folate 
concentration at baseline (≤7.5ng (mL) and receiving folic acid supplementation had a significant reduced risk of 
recurrence of adenomas 0.61 (0.42,0.90). Neither was there evidence of increased risk of advanced or multiple 
adenomas with folic acid supplementation.  
Conclusion No increased risk of recurrence of colorectal adenomas with folic acid supplementation of 1 mg/day for 5-6.5 years.   
Confounders adjusted for Analyses were adjusted for age, sex, extension group, and time between the start and the last follow up endoscopy. 
Relevance for our risk assessment 
purpose 
Yes, high relevance for this risk assessment.  
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Reference Figueiredo J.C., Grau M.V., Haile R.W., Sandler R.S., Summers R.W., Bresalier R.S., Burke C.A., McKeown-Eyssen G.E., Ba  
J.A. (2009) Folic acid and risk of prostate cancer: Results from a randomized clinical trial. Journal of the National Cancer 
Institute 101:432-435. 
Study design and type Secondary analysis of a RCT, USA. 
Objective Measure the risk of prostate cancer following supplementation of 1 mg folic acid. Measure to what extent folate status 
at baseline predicted prostate cancer. The study was carried out between 1994 and 2006.  
Number of participants, country 
and age 
651 randomised and 643 included in the analysis. 
Baseline characteristics of study 
subjects/cells 
Measured B vitamins, B12 concentration at baseline was lower in the folic acid supplementation group. 
Exposure, substance, food, (type 
and amount) 
Riboflavin, folate, vitamin B6 and vitamin B12 status at baseline, folic acid supplement use. 
Measurement of exposure 
(biomarker, internal validation) 
Intervention (folic acid supplementation or not), vitamin analysis in plasma. 
Follow-up period, drop-outs Median 7 years, for up to 10 years. 
Health outcome Prostate cancer. 
Measurement of outcome Medical reports for prostate cancer that was confirmed by histopathology.  
Statistical analysis Intent to treat. Cox proportional hazards models to measure the association between baseline vitamin B status and 
prostate cancer incidence and the effect of folic acid supplementation on prostate cancer. 
Results Folic acid supplementation was associated with a an increased risk of prostate cancer (HR 2.63: 95% CI 1.23 to 5.65) 
Plasma folate concentration was inversely associated with the risk of prostate cancer (borderline significant). 
Conclusion Evidence that daily supplementation with 1 mg of folic acid was associated with an increased risk of prostate cancer. 
Confounders adjusted for Several relevant. 
Relevance for our risk assessment 
purpose 
Relevant. Albeit secondary analysis, this is RCT with a long follow up time that demonstrates a substantial and 
significant effect of folic acid supplementation on cancer risk. 
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Reference Milne E., Greenop K.R., Bower C., Miller M., Van Bockxmeer F.M., Scott R.J., De Klerk N.H., Ashton L.J., Gottardo N.G., 
Armstrong B.K. (2012) Maternal use of folic acid and other supplements and risk of childhood brain tumors. Cancer 
Epidemiology Biomarkers and Prevention 21:1933-1941. 
Study design and type Case control study. 
Objective The aim of this study was to measure to what extent maternal folic acid supplementation other supplements was 
associated with childhood brain tumors. 
Number of participants, country 
and age 
327 cases from 10 Australian pediatric oncology centres. 867 controls selected randomly. 2005-2010. 
Baseline characteristics of study 
subjects/cells 
0-14 years, Australian. 
Exposure, substance, food, (type 
and amount) 
Folic acid supplements or other supplements during pregnancy. 
Measurement of exposure 
(biomarker, internal validation) 
Mailed questionnaires with questions on folic acid supplements or intake of other vitamins before and / or during 
pregnancy, specified by trimester. Non compliers were contacted by phone. 
Follow-up period, drop-outs N.a. 
Health outcome Childhood brain tumor. 
Measurement of outcome Children with tumors were recruited from 10 pediatric oncology centers. 
Statistical analysis Unconditional logistic regression. Exposure variables were whether or not folic acid was taken prepregnancy, first 
trimester or during the last two trimesters of pregnancy. A dose response relation between folic acid and risk of cancer 
was also estimated.  
Results Prepregnancy supplementation of folic acid was associated with a significant reduction in the odds of childhood brain 
tumor (OR 0.65 95CI 0.43 to 0.98). The effect of folic acid during pregnancy was lower and did not reach statistical 
significance. The effect of providing other vitamins or minerals was much less clear and did usually not attain statistical 
significance. 
Conclusion Inverse association of child brain tumors and prepregnancy use of folic acid. The effect of giving folic acid during 
pregnancy was less clear but there was some protection when given during early pregnancy. 
Confounders adjusted for Age, state of residence, ethnicity, maternal age, child’s birth year, maternal education, and source of data 
(questionnaire or phone). 
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Reference Milne E., Greenop K.R., Bower C., Miller M., Van Bockxmeer F.M., Scott R.J., De Klerk N.H., Ashton L.J., Gottardo N.G., 
Armstrong B.K. (2012) Maternal use of folic acid and other supplements and risk of childhood brain tumors. Cancer 
Epidemiology Biomarkers and Prevention 21:1933-1941. 
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Reference Amigou A., Rudant J., Orsi L., Goujon-Bellec S., Leverger G., Baruchel A., Bertrand Y., Nelken B., Plat G., Michel G., Haouy  
Chastagner P., Ducassou S., Rialland X., Hemon D., Clavel J. (2012) Folic acid supplementation, MTHFR and MTRR 
polymorphisms, and the risk of childhood leukemia: The ESCALE study (SFCE). Cancer Causes and Control 23:1265-1277. 
Study design and type Frequency matched case control study. 
Objective To measure the association between maternal folic acid supplementation before and during pregnancy and the risk of 
childhood acute leukemia. Measure the association between MTHFR and MTRR genetic polymorphisms and acute 
leukemia. 
Number of participants, country 
and age 
764 cases with childhood acute leukemia and 1681 controls. 
Baseline characteristics of study 
subjects/cells 
Cases identified from the French National registry of Childhood Hematopoietic Malignancies between January 2003 and 
December 2003. Cases and controls were less than 15 years. Randomly selected controls. 
Exposure, substance, food, (type 
and amount) 
Folic acid supplement used before or during pregnancy.  
Measurement of exposure 
(biomarker, internal validation) 
Telephone interview with the mothers 1-24 months after diagnosis (median 4 months) Collected information on other 
variables as well. Genotyped 97% of the cases and 48% of the controls.  
Follow-up period, drop-outs N.a. 
Health outcome N.a. 
Measurement of outcome Cases (childhood acute leukemia) vs. controls. Also measured the association in various sub-groups based on type of 
leukemia. 
Statistical analysis Multiple logistic regressions.  
Results Folic acid supplementation before and during pregnancy was associated with a substantial and significant reduction in 
the odds of childhood acute leukemia. Subtype of leukemia did not modify this association. 
Conclusion Maternal folic acid supplementation before or during pregnancy may reduce the risk of childhood acute leukemia. They 
also suggest that the genotype homozygous for variants of the genes required for folate metabolism may be a risk 
factor for acute leukemia. 
Confounders adjusted for Not stated. 
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Unmetabolised folic acid 
Reference Boilson A., Staines A., Kelleher C.C., Daly L., Shirley I., Shrivastava A., Bailey S.W., Alverson P.B., Ayling J.E., 
McDermott A.P., MacCooey A., Scott J.M., Sweeney M.R. (2012) Unmetabolized folic acid prevalence is widespread in 
the older Irish population despite the lack of a mandatory fortification program. American Journal of Clinical Nutrition 
96:613-21. 
Study design and type Cross sectional study, Ireland. 
Objective The aim of this study was to measure the basal (fasted) concentrations of unmetabolised folic acid in the plasma of an 
elderly population group exposed to the liberal voluntary fortification of foodstuffs in Ireland. 
Number of participants, country 
and age 
137 subjects were included in this cross sectional study, aged 60-86 years. Ireland with liberal voluntary folic acid 
fortification. 
Baseline characteristics of study 
subjects/cells 
Subjects excluded were those who had high creatinine concentration or high ALAT. 
Exposure, substance, food, (type 
and amount) 
Diet and folic acid supplement use. 
Measurement of exposure 
(biomarker, internal validation) 
A semi quantitative food frequency questionnaire measuring average intake previous 7 days.  
Follow-up period, drop-outs N.a. 
Health outcome N.a. 
Measurement of outcome Plasma folate and red blood cell folate analyses were conducted by using the Lactobacillus casei microbiological assay. 
UFA was measured by a column-switching HPLC method by using fluorescence detection after postcolumn coulometric 
oxidation and homocysteine analysis was performed by using a commercially available kit supplied. Genotyping of the 
MTHFR (methylenetetrahydrofolate reductase) 677C>T polymorphism (rs1801133) and the MTHFD1L (mitochondrial 
10-formyltetrahydrofolate synthetase) deletion insertion polymorphism [c.781–6823 ATT (7–9); rs3832406] was carried 
out.  
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Reference Boilson A., Staines A., Kelleher C.C., Daly L., Shirley I., Shrivastava A., Bailey S.W., Alverson P.B., Ayling J.E., 
McDermott A.P., MacCooey A., Scott J.M., Sweeney M.R. (2012) Unmetabolized folic acid prevalence is widespread in 
the older Irish population despite the lack of a mandatory fortification program. American Journal of Clinical Nutrition 
96:613-21. 
Statistical analysis Because a proportion of subjects had no folic acid intake (from vitamins or fortified food), there were many zeros in the 
data. Thus, exposure was categorised (total) habitual and recent folic acid intake to create two 5-category variables. 
The first category was no folic acid intake, and the remaining 4 categories were defined by the quartile cutoffs in the 
nonzero data. Groups were compared by using the independent t test or a 1-factor ANOVA as appropriate. 
Interrelations between the log-transformed variables were examined with scatter plots and Pearson product-moment 
correlations (excluding pairwise subjects with zero values of folic acid intake). Multiple regressions were performed with 
logUFA as the dependent variable and continuous variables or dummy indicator variables as predictors.  
Results Unmetabolised folic acid was detected in 94.1% of the cohort with a mean concentration of 0.39 nmol/L (range: 0.07-
1.59 nmol/L), accounting for 1.3% of total plasma folate. UMFA correlated significantly with intake of folic acid. In the 
participant not stating folic acid intake UFA concentrations were significantly lower than in subjects who recently had an 
intake. In this small study they found no significant correlations of the genotyping with MTHFR 677C>T, DHFR 19-bp 
interon deletion or MTHFDIL were found. 
Conclusion Unmetabolised folic acid was detected in 94.1% of the cohort with a mean concentration of 0.39 nmol/L (range: 0.07-
1.59 nmol/L), accounting for 1.3% of total plasma folate. 
Confounders adjusted for Not stated. 
Relevance for our risk assessment 
purpose 
Unmetabolised folic acid is found in a country with voluntary folic acid supplementation (no mandatory folic acid 
fortification) in the age group 60-86 years. 
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Reference Bailey R.L., Mills J.L., Yetley E.A., Gahche J.J., Pfeiffer C.M., Dwyer J.T., Dodd K.W., Sempos C.T., Betz J.M., Picciano 
M.F. (2010) Unmetabolized serum folic acid and its relation to folic acid intake from diet and supplements in a nationally 
representative sample of adults aged >60 y in the United States. American Journal of Clinical Nutrition 92:383-389. 
Study design and type Cross sectional study, USA. 
Objective The objective was to examine UMFA concentrations in relation to dietary and supplemental folic acid and status of 
biomarkers in the US population aged ≥60 y with use of data from NHANES. 
Number of participants, country 
and age 
1121 individuals aged ≥60 y. USA and NHANES 2001-2002.  
Baseline characteristics of study 
subjects/cells 
All eligible subjects were included, excluding those who had taken a food supplement before the fasting blood drawing, 
those who had self-reported anemia therapy or those who had high creatinine concentration or high ALAT. 
Exposure, substance, food, (type 
and amount) 
One 24-hour dietary recall was made and calculated intake of folate was done from diet and supplements. Information 
about dietary supplements was collected for the past 30 days. 
Measurement of exposure 
(biomarker, internal validation) 
UMFA and 5-methyltetrahydrofolate (5-MTHF) concentrations were determined by using a revised affinity/HPLC method 
with electrochemical (coulometric) detection Serum folate, red blood cell (RBC) folate and serum vitamin B12 were 
analysed by using the Quantaphase II radioassay from BioRad, Hercules, CA. 
Follow-up period, drop-outs N.a. 
Health outcome N.a. 
Measurement of outcome N.a. 
Statistical analysis Descriptive statistics (means and medians) were estimated for all variables by using PROC REG and PROC DESCRIPT in 
SAS-callable Sudaan. Any variables with a skewness >4 were log-transformed before group comparison analysis. The 
range of UMFA was quite large (0–273 nmol/L); the highest 2 data points (273 and 185 nmol/L) were extreme outliers 
and were winsorised to the next highest value of 85 nmol/L to remove the influence that these points. All statistical 
comparisons were controlled for sex, age, and race-ethnicity and presented as least-squares means. SEs for all statistics 
of interest were approximated by Taylor series linearisation, and significance was set at a Bonferroni-adjusted P value ≤ 
0.006 to account for multiple comparisons. 
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Reference Bailey R.L., Mills J.L., Yetley E.A., Gahche J.J., Pfeiffer C.M., Dwyer J.T., Dodd K.W., Sempos C.T., Betz J.M., Picciano 
M.F. (2010) Unmetabolized serum folic acid and its relation to folic acid intake from diet and supplements in a nationally 
representative sample of adults aged >60 y in the United States. American Journal of Clinical Nutrition 92:383-389. 
Results UMFA was detected in 38% of the population, with a mean concentration of 4.4 ± 0.6 nmol/L (median: 1.2± 0.2 
nmol/L). The group with UMFA (UMFA+) had a significantly higher proportion of folic acid supplement users than did 
the group without UMFA (60% compared with 41%). UMFA+ men and women also had higher supplemental and total 
(food + supplements) folic acid intakes than did their counterparts without UMFA. Forty percent of the UMFA+ group 
was in the highest quartile of total folic acid intake, but total folic acid intake was only moderately related to UMFA 
concentrations (r2 = 0.07). Serum folate concentrations were significantly higher in the UMFA+ group and were 
predictive of UMFA concentrations (r2 = 0.15). Serum 5-methyltetrahydrofolate and vitamin B-12 concentrations were 
higher in the UMFA+ group, whereas there was no difference between the two UMFA groups in red blood cell folate, 
serum homocysteine, or methylmalonic acid concentrations. 
Conclusion Approximately 40% of older adults in the United States have UMFA that persists after a fast, and the presence of UMFA 
is not easily explained in NHANES by folic acid intakes alone.  
Confounders adjusted for Sex, age, and race-ethnicity. 
Relevance for our risk assessment 
purpose 
Unmetabolised folic acid is found in subjects in countries with voluntary folic acid fortification. 
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Reference Morris M.S., Jacques P.F., Rosenberg I.H., Selhub J. (2010) Circulating unmetabolized folic acid and 5-
methyltetrahydrofolate in relation to anemia, macrocytosis, and cognitive test performance in American seniors. 
American Journal of Clinical Nutrition 92:1002-1002. 
Study design and type Cross sectional study, USA. 
Objective To look at the associations between higher folate status and anemia and cognitive test performance to circulating 
unmetabolised folic acid or 5-methyltetrahydrofolate (5MTHF). 
Number of participants, country 
and age 
1858 senior participants in NHANES 1999-2002. USA. Aged ≥60 years. The participants had normal renal function and 
reported no history of stroke, recent anemia therapy, or diseases of the liver, thyroid, or coronary arteries. 
Baseline characteristics of study 
subjects/cells 
Subjects excluded were those who had high creatinine concentration or high ALAT. 
Exposure, substance, food, (type 
and amount) 
One 24-hour dietary recall was made and calculated intake of folate was done from diet and supplements only from 
those included in 2001 and 2002. Information about dietary supplements was collected for the past 30 days.  
Measurement of exposure 
(biomarker, internal validation) 
The analyses included measurement of serum concentrations of vitamin B12 and folate, which were carried out by using 
the Quantaphase II Radioassay Kit (Bio-Rad Laboratories, Anaheim, CA). Plasma methylmalonic acid (MMA) was 
measured by gas chromatography–mass spectrometry with cyclohexanol derivatisation. Plasma homocysteine was 
analysed by using a commercially available fluorescence polarisation immunoassay kit (Abbott Laboratories, Abbott 
Park, IL) on the Abbott IMx analyser. Serum ferritin was measured by using the QuantaImmune Ferritin IRMA Kit (Bio-
Rad Laboratories). Serum C-reactive protein and cystatin C were quantified by particle-enhanced nephelometry, and 
serum creatinine concentration was based on the Jaffe reaction. 
Follow-up period, drop-outs N.a. 
Health outcome Anemia, macrocytosis and cognitive performance. 
Measurement of outcome The cognitive function of seniors was assessed by using a version of the Digit-Symbol Substitution Test (DSST) of the 
Wechsler Adult Intelligence Scale III—a screening test designed to detect cognitive impairment in adults and children. 
For the main data analyses, the score on the test as a continuously scaled term was used. However, for the purpose of 
presenting results of preliminary data analyses, subjects were classified as having performed poorly or well using a 
score of 34—the 20th percentile of the distribution—as the cutoff between the 2 categories. 
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Reference Morris M.S., Jacques P.F., Rosenberg I.H., Selhub J. (2010) Circulating unmetabolized folic acid and 5-
methyltetrahydrofolate in relation to anemia, macrocytosis, and cognitive test performance in American seniors. 
American Journal of Clinical Nutrition 92:1002-1002. 
Statistical analysis Multiple linear and logistic regression models were created for initial analyses of interaction and thereafter for the full 
models. All analyses were adjusted for sex, age, race-ethnicity, current smoking status, serum cystatin C, serum C-
reactive protein, and an alcohol-intake variable (ie, current alcohol intake for anemia and macrocytosis and self-reported 
history of alcohol abuse for cognitive test performance). Analyses focused on anemia were additionally adjusted for 
triceps skinfold thickness and self-reported diabetes status. Analyses focused on macrocytosis were additionally 
adjusted for body mass index, cancer history, and serum ferritin. Analyses focused on cognitive test performance were 
additionally adjusted for educational achievement and self-reported history of cancer and diabetes. 
Results Circulating unmetabolised folic acid was detected in ≈33% of the subjects and was related to an increased odds of 
anemia in alcohol users. In seniors with a serum vitamin B12 concentration <148 pmol/L or a plasma methylmalonic acid 
concentration ≥210 nmol/L, the presence compared with the absence of detectable circulating unmetabolised folic acid 
was related to lower cognitive test scores and lower mean cell volume. In the same subgroup, higher serum 5MeTHF 
was related to an increased odds of anemia and a marginally significantly decreased odds of macrocytosis. In seniors 
with a normal vitamin B12 status, a higher serum 5MeTHF concentration was related to higher cognitive test scores. 
Conclusion Unmetabolised folic acid was related to lower cognitive test scores in combination with low B12 concentration.  
Confounders adjusted for Sex, age, race-ethnicity, current smoking status, serum cystatin C, serum C-reactive protein, and an alcohol-intake 
variable See statistics.  
Relevance for our risk assessment 
purpose 
Unmetabolised folic acid in combination with low B12 concentration was associated with lower cognitive test scores. 
  
 
VKM Report 2015: 05  80 
 
Reference Obeid R., Kasoha M., Kirsch S.H., Munz W., Herrmann W. (2010) Concentrations of unmetabolized folic acid and 
primary folate forms in pregnant women at delivery and in umbilical cord blood. American Journal of Clinical Nutrition 
92:1416-1422. 
Study design and type Cross sectional study, Germany. 
Objective Investigate total folate, tetrahydrofolate (THF), 5-methyltetrahydrofolate (5-MTHF), formyl-THF, 5,10-methenylTHF, and 
folic acid concentrations in women and in umbilical cord blood at delivery. 
Number of participants, country 
and age 
87 pregnant women and 29 cord blood - including 24 mother/child pairs and 25 non-pregnant women who were not 
taking any supplement containing folic acid were included in the study.  
Baseline characteristics of study 
subjects/cells 
Subjects excluded were those who had high creatinine concentration or high ALAT. 
Exposure, substance, food, (type 
and amount) 
400 µg of folate daily (n=25) compared to those not supplemented pregnant women (n=61).  
Measurement of exposure 
(biomarker, internal validation) 
Just information of supplementation. No information on dietary data was collected. 
Follow-up period, drop-outs N.a. 
Health outcome N.a. 
Measurement of outcome Peripheral venous blood samples were obtained from mothers 1–12 h before birth. Concentrations of tHcy were 
measured by gas chromatography-mass spectrometry as described elsewhere (21). Concentrations of primary folate 
forms were measured in serum on an Acquity Ultra Performance LC system (Waters Corporation, Milford, MA) coupled 
to a MicroMass Quattro Premier XE tandem quadrupole mass spectrometer (Waters Corporation). Validation is 
described. 
Statistical analysis Comparisons of medians of 2 groups — supplemented and non-supplemented or pregnant and non-pregnant—were 
performed by using the Mann-Whitney U test. Possible differences in the means of different variables between maternal 
and cord serum were investigated by using a paired Student’s t test. Chi-square tests were performed to test 
differences in categorical variables. Correlations between different variables were examined by the Spearman’s test. 
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Reference Obeid R., Kasoha M., Kirsch S.H., Munz W., Herrmann W. (2010) Concentrations of unmetabolized folic acid and 
primary folate forms in pregnant women at delivery and in umbilical cord blood. American Journal of Clinical Nutrition 
92:1416-1422. 
Results Pregnant women who received 400 μg folic acid daily had higher total folate (P = 0.041), 5-MTHF (P = 0.049), and 
formyl-THF (P < 0.001) concentrations and slightly higher THF (P = 0.093) concentrations than did non-supplemented 
pregnant women. The measured folic acid concentrations >0.20 nmol/L in 38 (44%) pregnant women and in 55% of 
the cord serum samples, but these measurements were not explained by maternal supplement use. Concentrations of 
folic acid were nonsignificantly higher in cord blood from supplemented women than in cord blood from non-
supplemented women (P = 0.154). Proportions of folic acid to total folate in cord serum did not differ according to 
maternal supplement usage (0.54% compared with 0.43% in supplemented and non-supplemented women, 
respectively). Concentrations of folic acid did not differ between maternal and cord serum. However, folic acid 
constituted a significantly lower proportion of total folate in cord serum than in maternal serum. 
Conclusion Unmetabolised folic acid in more than one-half of cord blood samples was detected. Folic acid (400 μg/d) supplied 
during pregnancy is not likely to accumulate in the fetus, in contrast to 5-MTHF and THF, which accumulate in the 
foetus. 
Confounders adjusted for Not done.  
Relevance for our risk assessment 
purpose 
Unmetabolised folic acid does not seem to accumulate in cord blood from supplemented or non-supplemented women.  
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Reference Nguyen P., Tam C., O'Connor D.L., Kapur B., Koren G. (2009) Steady state folate concentrations achieved with 5 
compared with 1.1 mg folic acid supplementation among women of childbearing age. American Journal of Clinical 
Nutrition 89:844-852. 
Study design and type Randomised, 2-arm, open-label, intervention study. 
Objective To compare steady state folate concentrations in women of childbearing age who took 5 or 1.1 mg folic acid daily for 30 
weeks. 
Number of participants, country 
and age 
40 nonpregnant women between 18-45 years. Canada. 
Baseline characteristics of study 
subjects/cells 
Women did not take folic acid supplements. 
Exposure, substance, food, (type 
and amount) 
5 or 1.1 mg folic acid daily for 30 weeks. Folic acid was part of a multivitamin pill. 
Measurement of exposure 
(biomarker, internal validation) 
Plasma and red blood cell (RBC) folate. 
Follow-up period, drop-outs 30 weeks. 2 participants dropped out, 1 in each arm. 
Health outcome Plasma and RBC concentrations. 
Measurement of outcome Plasma and RBC folate concentrations measured at baseline and at weeks 2, 4, 6, 12 and 30. 
Statistical analysis The primary analysis was to compare the plasma and RBC folate concentrations between the 2 groups. 
Results Plasma folate concentrations increased to 165.3 + 109.9 nmol/L for the 5 mg folic acid group and to 96.8 + 41.1 
nmol/L for the 1.1 mg folic acid group by week 30 (differences were statistically significant).  Significant differences 
were also found in RBC folate concentrations between groups at weeks 4, 6, 12 and 30. Concentrations at week 30 
were 2339 + 782 and 1625 + 339 nmol/L for the 5 and 1.1 mg folic acid groups, respectively. 
At baseline, unmetabolised folic acid was detected in 70% and 65% of subjects in the 5 and 1.1 mg folic acid groups, 
respectively. By week 30, unmetabolised folic acid was detected n 58% of both groups.  
Conclusion The use of 5 mg folic acid produced higher blood folate concentrations, with a faster rate of folate accumulation, 
compared with 1.1 mg folic acid. 
Confounders adjusted for Other vitamins in the supplements were identical in the two groups. 
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Reference Sweeney M.R., Staines A., Daly L., Traynor A., Daly S., Bailey S.W., Alverson P.B., Ayling J.E., Scott J.M. (2009) 
Persistent circulating unmetabolised folic acid in a setting of liberal voluntary folic acid fortification. Implications for 
further mandatory fortification? BMC Public Health 9:295. 
Study design and type Two cross sectional studies, Ireland. 
Objective To examine the levels of circulatory unmetabolised folic acid in Irish adults and new-born infants before the proposed 
implementation of mandatory folic acid fortification. A secondary aim was to predict the increase in circulatory 
unmetabolised folic acid levels after fortification. 
Number of participants, country 
and age 
50 adult blood donors – non fasted (42 males – 8 females) (age 27-60 years) 
20 mothers delivered by caesarean section and their infants (umbilical cord) fasted for 8 hours (age 26-39 years). 
Baseline characteristics of study 
subjects/cells 
The 50 blood donors had consumed their normal diet prior to inclusion 
The 20 pregnant women had fasted 8 hours prior to surgery. 
Exposure, substance, food, (type 
and amount) 
Exposure normal diets which include voluntary fortification of foods like milk, yoghurt, vegetable spreads cereals and 
bread. None of the pregnant women used folic acid supplementation before delivery (the latest 120 days before). 
Measurement of exposure 
(biomarker, internal validation) 
Plasma and red cell folate were analysed by L. casei microbiological assay and unmetabolised folic acid was analysed by 
HPLC method. 
Follow-up period, drop-outs N.a. 
Health outcome None. 
Measurement of outcome  
Statistical analysis Wilcoxon signed rank test and for prediction regression analyses in SPSS were performed assuming a linear increase as 
total plasma folate increases. 
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Reference Sweeney M.R., Staines A., Daly L., Traynor A., Daly S., Bailey S.W., Alverson P.B., Ayling J.E., Scott J.M. (2009) 
Persistent circulating unmetabolised folic acid in a setting of liberal voluntary folic acid fortification. Implications for 
further mandatory fortification? BMC Public Health 9:295. 
Results Folic acid was present in 17 out of 20 babies (CI: 62.1%–96.8%) and 18 out of 20 mothers (fasted) (CI: 68.3%–
99.8%) comprising 1.31% of the total plasma folate. There was a significant correlation between the maternal plasma 
folate concentrations and maternal plasma unmetabolised folic acid concentrations (p = 0.007, r2 = 0.300), and 
maternal habitual folic acid intakes were correlated with maternal plasma folate concentrations (p = 0.001). A 
significant correlation between the maternal folic acid concentrations and cord blood folic acid concentrations (p = 
0.004, r2 = 0.378) was found. Unmetabolised folic acid was present in 49 out of 50 blood donors. After removing 2 
samples, which were outliers, the results show that habitual folic acid intakes are significantly correlated with plasma 
folate levels (p = 0.009 r2 = 0.115). Plasma folate was related to plasma unmetabolised folic acid concentrations (p = 
0.011, r2 = 0.110). The prediction showed that mandatory fortification of bread would result in an expected mean 
plasma folate increase of 3.1 μg/L. Unmetabolised folic acid to absolute levels of plasma folate was predicted on a 
population level of 0.623 μg/L for unmetabolised folic acid concentration, i.e. approximately 12% increase from current 
levels.  
Conclusion With the voluntary folic acid fortification unmetabolised folic acid was already present in most subjects and with a 
mandatory fortification a further 12% increase was suggested. 
Confounders adjusted for Is not mentioned. 
Relevance for our risk assessment 
purpose 
Unmetabolised folic acid is found in subjects in countries with voluntary folic acid fortification. 
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Summary Tables Meta-analyses 
Reference Mackerras, J T., C L. (2014) Folic Acid, Selected Cancers and All-cause Mortality: A Meta-analysis. International Food 
Risk Analysis Journal 4. 
Study types included 26 randomised controlled trials. 
Aim of review Systematic review of trials of folic acid supplementation on cancer incidence (total and site specific [colorectal, lung, 
breast, prostate]). In addition, the relation between folic acid and recurrence of colorectal adenoma, and total mortality. 
The search did not place any restrictions on health or disease outcome. 
Timespan literature search Search conducted May 2013. MEDLINE search from January 1, 2001 to 16 May 2013. Cochrane CENTRAL was also 
searched on May 16 2013. 
Category of exposure  
Dose range in included studies 0.4-20 mg folic acid/day. Trials were excluded if folic acid was administered in a broad multivitamin/mineral 
supplement. 
Timespan follow-up in included 
studies 
Trials had to administer folic acid and placebos for one year or longer and have a follow-up period of one year or 
longer. 
Comperators (placebo) Any placebos for folic acid had to be a blank or minimal dose of folic acid; factorial designs testing other substances 
were permitted. 
Evaluated for methodological 
quality? 
 
Grading of evidence methodology?  
Statistical analysis RRs were calculated using counts from each study. An overall weighted (unadjusted) RR for each outcome was 
calculated de novo from the numbers randomised and event numbers using the DerSimonian-Laird inverse variance 
random effects method. Its 95%CI was calculated using the Greenland-Robins formula.  
Results No significant associations were found. No association with all-cause mortality. RR for total incident cancer (13 studies): 
1.04.  
Conclusion No relation between folic acid supplementation, up to 5 mg per day, and risk of cancer or mortality. 
Relevance for our risk assessment 
purpose 
Low relevance as includes multiple vitamin supplementation studies. 
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Reference Qin X., Cui Y., Shen L., Sun N., Zhang Y., Li J., Wang B., Xu X., Huo Y., Wang X. (2013) Folic acid supplementation and 
cancer risk: A meta-analysis of randomized controlled trials. International Journal of Cancer 133:1033-1041. 
Study types included 15 randomised controlled trials. 
Aim of review To systematically evaluate the effect of folic acid on cancer risk, not including post-treatment trial observational follow-
up studies.  
Timespan literature search Search of MEDLINE database from January 1966 to October 2012.  
Category of exposure  
Dose range in included studies 0.5 – 40 mg/day. 
Timespan follow-up in included 
studies 
At least 6 months. 
Comperators (placebo)  
Evaluated for methodological 
quality? 
Studies were assessed for quality of randomisation, blinding, reporting of withdrawals, generation of random numbers 
and concealment of allocation (possible score 0-5). Quality of the 15 trials ranged from 3-5. 
Grading of evidence methodology?  
Statistical analysis RRs were used to measure the effect of folic acid supplementation on risk of cancer using a random-effects model. 
Possible effect modifications of several variables were examined. 
Results Overall, folic acid supplementation had no significant effect on total cancer incidence, colorectal cancer, other 
gastrointestinal cancer, prostate cancer, other genitourinary cancer, lung cancer, breast cancer, hematological 
malignancy and total cancer mortality. A significantly reduced risk was found for melanoma (RR 0. 47; 0.23-0.94). A 
higher total cancer incidence risk was found in trials with a high percent use of lipid lowering drugs or with lower 
percent baseline hypertension. 
Conclusion Folic acid supplementation has no significant effect on the incidence of total cancer or those mentioned under results, 
except for a reduced risk of melanoma. 
Relevance for our risk assessment 
purpose 
Low relevance as includes multiple vitamin supplementation studies. 
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Reference Vollset S.E., Clarke R., Lewington S., Ebbing M., Halsey J., Lonn E., Armitage J., Manson J.E., Hankey G.J., Spence J.D., 
Galan P., Bonaa K.H., Jamison R., Gaziano J.M., Guarino P., Baron J.A., Logan R.F.A., Giovannucci E.L., Den Heijer M., 
Ueland P.M., Bennett D., Collins R., Peto R. (2013) Effects of folic acid supplementation on overall and site-specific 
cancer incidence during the randomised trials: Meta-analyses of data on 50 000 individuals. The Lancet 381:1029-1036. 
Study types included 13 randomised trials: 10 on prevention of cardiovascular disease, 3 in patients with colorectal adenoma. 
Aim of review To assess any effects on site-specific cancer rates in randomised trials of folic acid supplementation, at doses higher 
than those obtained from fortification. 
Timespan literature search All trials completed before 2011. 
Category of exposure  
Dose range in included studies 0.5-2.5 mg/day. One trial with 40 mg/day, in renal patients. 
Timespan follow-up in included 
studies 
Treatment duration of at least one year. Average treatment duration 5.2 years. 
Comperators (placebo)  
Evaluated for methodological 
quality? 
 
Grading of evidence methodology?  
Statistical analysis The investigators obtained individual-level data from each trial, totalling 49 621 participants. Log-rank analyses were 
used to calculate cancer incidence rate ratio.  
Results Folic acid supplementation had no significant effect on overall cancer incidence during the first 5 years of treatment in 
the trials of cardiovascular disease prevention (RR=1.06, 95% CI 0.99-1.13). No trends towards greater effect with 
longer treatment. No significant effect on the incidence of cancer of the large intestine, prostate, lung, breast or any 
other specific site. In the 3 trials among patients with colorectal adenoma, the meta analysis found a nonsignificant RR= 
1.33 (95% CI 0.98-1.80). 
Conclusion Folic acid supplementation had no significant effect on cancer incidence. 
Relevance for our risk assessment 
purpose 
Low relevance as includes multiple vitamin supplementation studies. 
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Reference Baggott J.E., Oster R.A., Tamura T. (2012) Meta-analysis of cancer risk in folic acid supplementation trials. Cancer 
Epidemiology 36:78-81. 
Study types included 6 randomised placebo-controlled trials of folic acid supplementation. 
Aim of review To evaluate the risk of cancer secondary to folic acid supplementation.  
Timespan literature search Search of PubMed on June 11, 2009. Subsequently, PubMed was searched on a nearly daily basis using the key word 
‘folate’ to update the search – it is not clear which was the last search date. 
Category of exposure  
Dose range in included studies Folic acid: 0.5 – 2.5 mg/day. Supplements included other nutrients.  
Timespan follow-up in included 
studies 
Duration of intervention 12 months or more. Average duration 7 years. 
Comperators (placebo)  
Evaluated for methodological 
quality? 
Not mentioned. 
Grading of evidence methodology?  
Statistical analysis Weighted analysis of trial-specific effects. RR provided. 
Results One of the six trials found a significantly increased risk of cancer. Overall, cancer incidences were higher in the folic 
acid-supplemented groups than in the non-folic acid- supplemented groups (RR=1.21; 1.05-1.39).  
Conclusion Overall, cancer incidences were higher in the folic acid-supplemented groups than in the non-folic acid- supplemented 
groups. 
Relevance for our risk assessment 
purpose 
Low relevance as includes multiple vitamin supplementation studies. 
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Reference Wien T.N., Pike E., Wisloff T., Staff A., Smeland S., Klemp M. (2012) Cancer risk with folic acid supplements: A 
systematic review and meta-analysis. BMJ Open 2. 
Study types included 19 studies, including 12 randomised controlled trials. 10 of the 12 trials reported overall cancer incidence. 
Aim of review To explore if there is an increased cancer risk associated with folic acid supplements.  
Timespan literature search Search conducted March-May 2010, using MeSH and free-text search terms for folate, folic acid, cancer and neoplasm. 
The following electronic databases were searched: EMBASE, Ovid MEDLINE, Cochrane Library, Centre for Reviews and 
Dissemination, NHS evidence, Clincial evidence, and others.  
Category of exposure  
Dose range in included studies > 0.4 mg/day. Up to 40 mg/day (renal disease patients). Folic acid with or without other B-vitamins. 
Timespan follow-up in included 
studies 
 
Comperators (placebo) Any. 
Evaluated for methodological 
quality? 
The quality of the included studies was assessed using the Cochrane Collaboration’s tool for Risk of Bias assessment for 
RCTs and checklists for cohort and case-control studies. 
Grading of evidence methodology?  
Statistical analysis When feasible, the authors pooled data by meta-analyses with Cochrane Collaboration software and used random-
effects model calculating RRs. PRISMA statement for reporting systematic reviews and meta-analyses. RRs are reported. 
Results In the 10 RCTs reporting overall cancer incidence, RR associated with folic acid supplements = 1.07 (1.00-1.14). Six 
RCTs reported prostate cancer incidence, with a combined RR=1.24 (1.03-1.49). No significant increased risk for any 
other cancer type. Six trials reporting overall cancer mortality found no significant differences between folic acid 
supplementation versus not (RR=1.09, 95% CI 0.90-1.30). 
Conclusion Meta-analysis of 10 RCTs showed a borderline significant increase in incidence of overall cancer in the folic acid group. 
Prostate cancer was the only site-specific cancer where folic acid significantly increased the risk. 
Relevance for our risk assessment 
purpose 
Low relevance as includes multiple vitamin supplementation studies. 
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Reference Figueiredo J.C., Mott L.A., Giovannucci E., Wu K., Cole B., Grainge M.J., Logan R.F., Baron J.A. (2011) Folic acid and 
prevention of colorectal adenomas: A combined analysis of randomized clinical trials. International Journal of Cancer 
129:192-203. 
Study types included Including 3 randomised controlled studies.  
Aim of review To determine the effect of folic acid supplementation and the risk of adenoma in patients with an adenoma history. 
Timespan literature search Search was not time limited. Keywords were folic acid supplementation, trial and colorectal adenoma. 
Category of exposure Folic acid supplementation. 
Dose range in included studies 0.5 to 1 mg folic acid supplementation per day. 
Timespan follow-up in included 
studies 
From 6 months up to 42 months. 
Comperators (placebo) Yes, all were placebo controlled studies. 
Evaluated for methodological 
quality? 
The results from the three included studies were adjusted for confounding, but the Meta-analysis by itself was not 
adjusted. Only one study (the Harvard study) checked for folic acid compliance through blood status, while the two 
other checked with pill count.  
Grading of evidence methodology?  
Statistical analysis The investigators obtained individual-level data from each trial (n=2632). Standard random-effects meta-analysis 
methods. 
Results The random-effects meta-analysis the RR was 0.98 (95% CI 0.82,1.17) for all adenomas and 1.06 (0.81,1.39) for 
advanced lesions., however for those who received folate for over 3 years, the risk for adenomatous lesion was 
increased. The risk for associated with treatment was the highest for the occurrence of advanced lesions. 
Conclusion Overall, the risk of an adenomatous lesion was not increased or decreased among patients with a history of adenomas 
and who received folate supplementation for up to 3.5 years. 
Relevance for our risk assessment 
purpose 
This is the most relevant meta-analysis for our purpose because it includes only study with folic acid supplementation. 
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Reference Fife J., Raniga S., Hider P.N., Frizelle F.A. (2011) Folic acid supplementation and colorectal cancer risk: A meta-analysis. 
Colorectal Disease 13:132-137. 
Study types included 3 randomised or pseudorandomised trials. 
Aim of review To determine the effect of folic acid supplementation on colorectal cancer, the risk of adenoma or advanced 
adenomatous lesions, including RCR. 
Timespan literature search Search conducted July 2008. MEDLINE, EMBASE, Cochrane and CINAHL. 
Category of exposure  
Dose range in included studies 1 mg/day for 3 years, 0.5 mg/day for 3 years, 2.5 mg/day for 5 years (+50 mg B6 and 1 mg B12). 
Timespan follow-up in included 
studies 
Supplementation for 3-years (1 mg/day) and 6 or 8 years colonoscopic follow-up, 0,5 mg/day 3 years follow-up, 2.5 
mg/day 5 years follow-up. 
Comperators (placebo)  
Evaluated for methodological 
quality? 
 
Grading of evidence methodology?  
Statistical analysis Weighted treatment effect (using fixed effects) was calculated across trials using RevMan. 
Results Overall, the risk of an adenomatous lesion was not increased among patients who received folate supplementation for 
up to 3 years, however for those who received folate for over 3 years, the risk for adenomatous lesion was increased. 
The risk for associated with treatment was the highest for the occurrence of advanced lesions. After 3 years; OR was 
1.09 (0.93-1.28). Above 3 years; OR was 1.35 (1.06-1.70). 
Conclusion Folate status is inversely related to the risk of developing colorectal cancer. 
Relevance for our risk assessment 
purpose 
Low relevance as includes multiple vitamin supplementation studies. 
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Reference Ibrahim E.M., Zekri J.M. (2010) Folic acid supplementation for the prevention of recurrence of colorectal adenomas: 
Metaanalysis of interventional trials. Medical Oncology 27:915-918. 
Study types included 5 Meta-analysis of interventional randomised, placebo controlled studies. Citations from PubMed, EMBASE, Cochrane 
databases and abstract from relevant proceedings. 
Aim of review Prospective phase II and III randomised clinical trials that directly compared folic acid supplementation given in a 
defined dose and a planned duration versus placebo to prevent recurrence of colorectal adenomas. 
Timespan literature search Comprehensive search for citation from PubMed, EMBASE, Cochrane database and abstracts of relevant proceedings. 
Time span not give 
Category of exposure  
Dose range in included studies 0.5 mg/day for one year in one study, 1 mg /day of folic acid in 1 year in one study, for 2 years in a second study and 3 
years in a third study, 5 mg/day for 1 year. 
Timespan follow-up in included 
studies 
Follow up for 3 years in 2 studies 
Comperators (placebo)  
Evaluated for methodological 
quality? 
The heterogeneity in methodologies was however significant. 
Grading of evidence methodology?  
Statistical analysis Data was analysed using RevMan. 
Results Examination of the effect of dose of folic acid showed that the two studies that had used 1 mg/day favoured folic acid 
over placebo with an odd ratio of 0.62. However the overall effect for all the included studies was not significant. OR 
was 1.08 (0.87-1.33). 
Conclusion Folate supplementation had no protective effect on the recurrence of colorectal adenomas, nor had it a positive 
outcome on the number of recurrent polyps pr patients. 
Relevance for our risk assessment 
purpose 
Low relevance as includes multiple vitamin supplementation studies. 
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